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ABSTRACT 
 
Purpose: To determine the proportion of patients experiencing improvement or remission 
of prediabetes or type 2 diabetes mellitus (T2DM) 12 months following laparoscopic 
sleeve gastrectomy (LSG). 
Methods: From May 2011 to September 2013, 171 patients underwent LSG and 
consented to participate in the study. Based on laboratory values, medical history, and 
antidiabetic medication use, 24 (14.0%) patients had prediabetes and 67 (39.2%) had 
T2DM. Re-evaluation of laboratory values and medication use was conducted at 3, 6, and 
12 months post-surgery to assess for changes in glycemic control and diabetes status. 
Results: Of 11 prediabetic patients that returned 12 months post-surgery, 9 (81.8%) 
achieved remission of prediabetes. 6 of 24 (25%) T2DM patients that returned for 12 
month follow-up achieved remission and 5 (20.8%) experienced improvement of T2DM. 
Conclusions: Obese patients may experience improvement or remission of prediabetes or 
T2DM within 12 months following LSG. The mechanisms by which improvement or 
remission occur are not fully understood. More research is needed to determine the long-
term implications of LSG on T2DM complications, prevalence, mortality, etc. before it 
can be considered as a treatment for prediabetes or T2DM. 
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Chapter 1: Introduction 
1.1 Background and Rationale 
 
Obesity is defined as a condition of abnormal or excessive fat accumulation in 
adipose tissue to such an extent that health may be adversely affected (WHO Consultation 
on Obesity, 2000). Obesity was recently recognized as a disease by the American Medical 
Association (American Medical Association, 2013) and is a risk factor for the 
development of comorbid conditions such as hypertension, type 2 diabetes mellitus 
(T2DM), cardiovascular disease, osteoarthritis, sleep apnea, certain cancers, and 
premature mortality (Picot et al., 2009). The amount of excess fat, its distribution 
throughout the body, and the associated comorbidities can vary between individuals 
living with obesity (WHO Consultation on Obesity, 2000). Overweight and obesity are 
most commonly classified by an individual’s body mass index (BMI) and is calculated 
using an individual’s height and weight with units kg/m2 (WHO Consultation on Obesity, 
2000). Overweight is defined as 25 kg/m2 ≤ BMI < 30 kg/m2, whereas obesity is defined 
as BMI ≥ 30 kg/m2 and is broken down by Health Canada into three separate classes, 
Class I (30 kg/m2 ≤ BMI < 35 kg/m2), II (35 kg/m2 ≤ BMI < 40 kg/m2), and III (BMI ≥ 40 
kg/m2), with an increased risk of developing health problems as BMI increases (Health 
Canada, 2003).  
BMI is an indirect surrogate measure of body fat commonly used in clinical 
settings and epidemiological studies (WHO Consultation on Obesity, 2000).  It is useful 
as a crude measure of population-level weight status and a reasonably reliable screening 
tool, as it correlates highly with direct measure of excess fat and health risk (Belle et al., 
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2007).  However, the accuracy of BMI may vary on an individual level as it does not 
distinguish between fluid retention versus adiposity, cases of extreme height or muscle 
mass, ethnic differences on body composition, or the location of fat (WHO, 1995; 
Wellens et al., 1996). Alternatively, waist circumference is a convenient and simple 
measurement that correlates closely with BMI but is unrelated to height and is an 
approximate measurement of intra-abdominal fat mass and total body fat (WHO 
Consultation on Obesity, 2000).  
Excess abdominal fat is a risk factor for high blood pressure, high cholesterol, 
T2DM, heart disease, and stroke (Heart & Stroke Foundation, 2010). Males and females 
with waist circumferences greater than 102 cm and 88 cm, respectively are at an 
increased risk for developing health problems (Heart & Stroke Foundation, 2010). 
Decreases in waist circumference reflect decreases in risk factors for cardiovascular 
disease and other chronic diseases as mentioned above, though the risks vary in different 
populations (WHO Consultation on Obesity, 2000). Obesity, particularly abdominal 
obesity, is a well-known risk factor for the development of prediabetes and T2DM. 
Abdominal fat promotes the secretion of inflammatory chemicals from adipose cells 
which decreases insulin sensitivity by disrupting the function of insulin responsive cells 
and their ability to respond to insulin (Diabetes UK, 2014). Adipose tissue also secretes a 
large number of proteins such as adipsin/ASP and resistin, which decrease insulin 
sensitivity (Lazar, 2005). This condition is known as insulin resistance and is a trigger for 
the development of T2DM (Diabetes UK, 2014). 
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Diabetes is a chronic condition considered by many to be the model chronic 
disease; it is progressive, managed rather than cured, and creates a burden on both 
patients and the health care system (Purnell & Flum, 2009). Diabetes can lead to long-
term complications affecting the eyes, kidneys, and nerves (Goldenberg & Punthakee, 
2013; Maggio & Pi-Sunyer, 2003) and adults with diabetes are two to four times more 
likely to have a stroke or develop heart disease (American Heart Association, 2012). The 
Canadian Diabetes Association (CDA) defines the clinical diagnosis of diabetes as based 
on blood glucose levels, specifically a 2-hour plasma glucose in a 75g oral glucose 
tolerance test (2hPG in a 75g OGTT) ≥ 11.1 mmol/L, or levels of fasting plasma glucose 
(FPG) ≥ 7.0 mmol/L, or glycated haemoglobin (A1c) ≥ 6.5% (Goldenberg & Punthakee, 
2013). There are three main types of diabetes, type 1 diabetes, T2DM, and gestational 
diabetes with T2DM being the most common worldwide [International Diabetes 
Federation (IDF), 2013]. 
T2DM is a multifactorial disease characterized by high blood glucose levels 
resulting from the body’s inability to produce, secrete, or use insulin properly (Abbatini et 
al., 2012; Canadian Diabetes Association, 2014; Goldenberg & Punthakee, 2013). The 
development of T2DM is characterized by resistance to insulin action but it is also 
associated with progressive β-cell failure in the pancreas and impaired actions of the 
incretin hormones (Abbatini et al., 2012; Opinto et al., 2013; Zimmet & Alberti, 2012). 
Incretins, namely glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP), are gastrointestinal hormones that stimulate a decrease in blood 
glucose levels by causing the β-cells in the pancreas to secrete insulin (Opinto et al., 
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2013). Incretins also regulate postprandial glucose disposal through the inhibition of 
glucagon secretion and delayed gastric emptying (Opinto et al., 2013). Furthermore, 
GLP-1 has an inhibitory effect on appetite and food intake and its impaired effects in 
individuals with T2DM may explain why the majority of patients with diabetes are 
overweight or obese (Gutzwiller et al., 1999). While there does not appear to be a major 
secretory defect in GIP secretion in diabetic patients, the actions of GIP are severely 
impaired (Opinto et al., 2013). On the other hand, there is a decreased secretion of GLP-1 
in diabetic patients, particularly following ingestion of a mixed meal as well as a reduced 
potency in the insulinotropic effects of GLP-1 in patients with T2DM (Opinto et al., 
2013). 
In both 1997 and again in 2003, the American Diabetes Association’s Expert 
Committee on Diagnosis and Classification of Diabetes Mellitus identified a group of 
individuals whose glucose levels were elevated from normal but not enough to meet the 
criteria for the diagnosis of T2DM [American Diabetes Association (ADA), 2013]. These 
individuals were referred to as having impaired fasting glucose (IFG) or impaired glucose 
tolerance (IGT). IFG is defined as FPG levels ranging from 6.1 mmol/L to 6.9 mmol/L 
while IGT is defined as 2hPG in a 75g OGTT levels between 7.8 mmol/L and 11.0 
mmol/L (Goldenberg & Punthakee, 2013). The condition of IGT is more strongly 
associated with cardiovascular disease outcomes than is IFG (Goldenberg & Punthakee, 
2013). These conditions of IFG and IGT are now commonly known as prediabetes (ADA, 
2013; Goldenberg & Punthakee, 2013). Individuals living with prediabetes are considered 
to be at a relatively high risk for developing T2DM and cardiovascular disease in the 
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future; however, not all individuals with prediabetes will progress to T2DM (ADA, 2013; 
Goldenberg & Punthakee, 2013). 
 Preventing, or delaying, the onset of T2DM in high-risk individuals and those 
living with prediabetes is possible. The Diabetes Prevention Program research group 
studied the effects of lifestyle modifications and metformin use in reducing the incidence 
of T2DM in patients with elevated glycemic levels (Knowler et al., 2002). The results of 
this study found that both lifestyle modification and the use of metformin reduced the 
incidence of T2DM in prediabetic patients with lifestyle modification being more 
effective than the use of metformin (Knowler et al., 2002). It follows that both the CDA 
and the American Diabetes Association (ADA) recommend lifestyle modifications 
including a 5-7% loss of body weight as well as regular physical activity (150min/week) 
to prevent the progression of prediabetes to T2DM, with the use of metformin being 
recommended for very high-risk individuals (ADA, 2013; Ransom et al., 2013). 
A patient-centred approach to the management of T2DM is stressed by 
organizations worldwide. While some individuals are able to manage their diabetes 
through lifestyle modifications, particularly weight loss and physical activity, the majority 
of individuals require pharmacological intervention (Zimmet & Alberti, 2012). The initial 
recommended treatment, if not contraindicated, is metformin; but due to the progressive 
nature of T2DM most individuals will require the use of multiple medications and then 
eventually insulin therapy (ADA, 2013; Harper et al., 2013).  
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T2DM is closely associated with obesity. The prevalence of T2DM and obesity 
are increasing in parallel worldwide and an estimated 90% of individuals living with 
T2DM are overweight or obese (Abbatini et al., 2012; Maggio & Pi-Sunyer, 2003; 
Zimmet & Alberti, 2012). From a global perspective, it is estimated that 382 million 
people or 8.3% of the adult population worldwide are living with diabetes (IDF, 2013) 
while 35% of the world’s adults are overweight and 12% are obese (WHO Global Health 
Observatory, 2014). From a Canadian perspective, Newfoundland and Labrador (NL) has 
the highest prevalence of both diabetes [Canadian Diabetes Association (CDA), 2010a] 
and obesity (Twells et al., 2014) in the country, 9.3% and 27.7% respectively. Recently, 
bariatric surgery was recommended as an innovative treatment option for the 
management of T2DM in obese patients (Buchwald & Oien, 2013; Mechanick et al., 
2013; Wharton et al., 2013). 
Bariatric surgery is currently the most effective and sustainable treatment for 
obesity and is one of the most commonly performed gastrointestinal procedures 
worldwide (Buchwald & Oien, 2013; Mechanick et al., 2013). There are many different 
types of bariatric surgical procedures and they can be classified as being restrictive, 
malabsorptive, or a combination of both. With respect to surgical technique, there has 
been a shift towards performing surgeries laparoscopically as opposed to open surgery as 
it decreases time spent in the hospital as well as recovery time for patients. Some of the 
more popular procedures are gastric bypass, biliopancreatic diversion, adjustable gastric 
banding, and laparoscopic sleeve gastrectomy (LSG).  
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LSG is a non-reversible, restrictive surgical procedure in which approximately 
75%-80% of the stomach is removed, leaving behind a “sleeve” with a reduced gastric 
volume of 60-100 mL (Karmali et al., 2010; Porier et al., 2011). Once considered to be an 
investigational procedure, LSG has been growing in popularity amongst surgeons and 
patients and in 2013 was recommended as a primary bariatric and metabolic procedure to 
be performed in patients requiring weight loss and/or metabolic control (Mechanick et al., 
2013). LSG has been shown to produce good short-term weight loss in patients. One 
randomized controlled trial found that patients lost 27.9% of their total body weight one 
year post-surgery (Victorzon, 2012). Clinically expected percent excess weight loss 
(%EWL) within 6 to 36 months following LSG is 45-60%, and occurs rapidly after 
surgery (Victorzon, 2012). A Canadian study, with an average follow-up time of 10 
months (range: 2–23 months) found that patients had an average weight loss of 27.4 kg 
and experienced an average change in BMI of 10.4 kg/m2 (Behrens et al., 2011). In 
Canada, eligible patients for bariatric surgery are those with class II obesity (35 kg/m2 ≤ 
BMI ≤ 40 kg/m2) and one or more obesity-related comorbidity or those with class III 
obesity (BMI ≥ 40 kg/m2; Lau et al., 2007).  
While the mechanism by which improvement or remission of T2DM occurs 
following bariatric surgery is complex and not fully understood, it appears to be due, in 
part, to weight loss. However, the degree of improvement does not always correlate with 
the amount of weight lost increasing the likelihood of the involvement of gut hormones 
and diet in comorbid resolution following surgery (Poirier & Auclair, 2014).  
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In May 2011, a new bariatric surgery program began offering residents of NL 
access to LSG in their own province. At the same time the Translational Research 
Program in Bariatric Care commenced with the aim of bringing together a team of 
researchers, health care professionals, and policy and decision makers to design and carry 
out meaningful research projects to address gaps in the literature surrounding LSG, a 
relatively new stand-alone bariatric procedure. One of the emerging research projects was 
an inception cohort study [i.e., Newfoundland and Labrador Bariatric Surgery Cohort 
Study (NL BaSco study)]. The overall purpose of the study was to examine short-, mid-, 
and long-term clinical (weight loss and resolution of comorbidities), economic (health 
services use and costs), and quality of life outcomes in patients undergoing LSG in NL.  
In 2011, when this study began, LSG was considered to be an investigational 
procedure with limited research on the outcomes of LSG with respect to weight loss, 
complications, and the effect on comorbid conditions such as T2DM (Mechanick et al., 
2008). Although there are an increasing number of studies published on LSG outcomes 
there is a lack of Canadian data on this relatively new procedure. With the start of a 
bariatric program in NL there is a unique opportunity to study the short-, mid-, and long-
term outcomes of LSG. With the recent shift in thinking of bariatric surgery as not only a 
treatment for obesity but also as a potential treatment for T2DM, this research will add to 
the current literature on the effectiveness of LSG in treating T2DM from a Canadian 
health care perspective. 
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1.2 Purpose 
 
 The primary purpose of this arm of the larger cohort study was to investigate the 
effectiveness of LSG in improving or inducing remission of prediabetes or T2DM in 
bariatric surgery patients living in NL by determining the proportion of patients 
experiencing improvement or remission of prediabetes or T2DM 12 months post-surgery, 
taking into consideration the concomitant use of diabetes medications. A second purpose 
was to investigate changes in: (1) laboratory values including: FPG, A1c, fasting lipid 
panel, triglycerides; (2) blood pressure, weight; and (3) dosage and number of antidiabetic 
medications prescribed. 
The study was designed to answer the following primary research questions: 
1. What proportion of patients experience improvement or remission of prediabetes 
12 months following LSG? What changes, if any, occur in levels of FPG and A1c 
in prediabetic patients 12 months following surgery? 
2. What proportion of patients experience improvement or remission of T2DM 12 
months following LSG? What changes, if any, occur in levels of FPG and A1c in 
patients with T2DM 12 months following surgery? 
The secondary research questions addressed by this study were: 
1. What baseline factors, if any, can be used to predict the likelihood of a patient 
achieving remission of prediabetes or T2DM 12 months post-surgery? 
2. Is the amount of weight lost 12 months post-surgery associated with changes in 
blood pressure or levels of FPG, A1c, triglycerides, high-density lipoprotein 
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(HDL), low-density lipoprotein (LDL), or total cholesterol post-surgery? Is the 
amount of weight lost associated with remission of prediabetes or T2DM 12 
months post-surgery? 
3. What changes, if any, occur in weight, blood pressure, triglycerides, and fasting 
lipid panel levels, and dose and number of antidiabetic medications prescribed 12 
months post-surgery? 
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Chapter 2: Literature Review 
 
 The purpose of this literature review is to review and summarize the gaps in the 
clinical literature on the remission or improvement of prediabetes and T2DM following 
LSG. First will be an overview of obesity, prediabetes, T2DM, and bariatric surgery from 
a global, national, and provincial perspective. Second will be a review of the literature 
comparing the effectiveness of LSG to other types of bariatric surgery in resolving T2DM 
followed by a review of the existing literature on the efficacy of LSG in resolving T2DM. 
2.1 Epidemiology of Obesity 
 
 2.1.1 Global trends. The prevalence of overweight and obesity is increasing in 
both developed and developing countries (Stevens et al., 2012; WHO Consultation on 
Obesity, 2000). In 2008, 1 in 3 adults worldwide was overweight and 1 in 9 was obese 
(Stevens et al., 2012). A paper by Stevens et al. (2012) estimated trends in overweight 
and obesity in 199 countries and found that the age-standardized prevalence of obesity 
nearly doubled from 6.4% to 12.0% between 1980 and 2008, with half of this increase 
occurring in the last 8 years, from 2000 to 2008. During this same period, the global 
prevalence of overweight increased from 24.4% to 34.4%. Not only are obesity rates 
continuously rising globally, but the rate of growth appears to have accelerated in the last 
decade (Stevens et al., 2012).  
 Obesity rates vary by country and region. In 2008, the highest obesity prevalence 
was found in the regions of North Africa and Middle East, Central and Southern Latin 
America, Southern Sub-Saharan Africa, and North America with prevalences ranging 
from 27.4% to 31.1% (Stevens et al., 2012). Based on the most recent data available from 
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the World Health Organization (WHO), the countries with the highest percentage of 
obese adults (BMI ≥ 30 kg/m2) were Nauru (78.5%), American Samoa (74.6%), and 
Tokelau (63.4%) (WHO, 2012a). The lowest percentage of obese adults was found in 
Vietnam (0.5%), India (0.7%), and Lao People’s Democratic Republic (1.2%) (WHO, 
2012a). The WHO Monitoring of Trends and Cardiovascular Disease (MONICA) study 
reported that, in general, women have higher rates of obesity than men whereas men may 
have higher rates of overweight than women (WHO Consultation on Obesity, 2012). 
 2.1.2 Obesity in Canada. Obesity rates are rising in Canada. The prevalence of 
adult obesity (BMI ≥ 30 kg/m2) increased from 6.1% in 1985 to 18.3% in 2011 (Twells et 
al., 2014). During this time the prevalence of all obese classes increased and 
disproportionate increases were seen in the higher classes of obesity (Twells et al., 2014). 
Rates of overweight in Canada are also rising with an increase from 27.8% in 1985 to 
33.6% in 2011 (Twells et al., 2014). Based on the most recent self-reported data available 
from Statistics Canada (2013), 62.0% of males and 45.1% of females in Canada are 
overweight or obese.  
 Just as obesity rates vary globally between countries and within regions, obesity 
rates in Canada vary by province and territory. Data of self-reported obesity rates in 2011 
varied from a low of 14.5% in British Columbia to a high of 27.7% in Newfoundland and 
Labrador (Twells et al., 2014). In fact, the prevalence of obesity in all provinces and 
territories increased in the period between 2000/1 and 2011 (Twells et al., 2014). In 
general, lower prevalence rates of obesity were observed in western Canada compared to 
eastern Canada and from a regional perspective, the prevalence of obesity tends to be 
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lower in urban areas compared to rural areas (Twells et al., 2014). Similar trends have 
been reported in the prevalence of overweight in Canada, the lowest prevalence being 
31.3% in British Columbia and the highest being 41.8% in Newfoundland and Labrador. 
In contrast, between 2000/1 and 2011 the provinces of Prince Edward Island, New 
Brunswick, and Alberta have experienced slight decreases in the prevalence of 
overweight individuals (Twells et al., 2014). 
 2.1.3 Obesity in Newfoundland and Labrador. NL has the highest prevalence of 
overweight and obesity in the country. In 2013, self-reported data from Statistics Canada 
indicated that 69.2% of the population was overweight or obese (Statistics Canada, 2013). 
A recent study by Twells et al. (2014) using data from the Statistics Canada Canadian 
Community Health Surveys reported that in 2011 the prevalence of obesity in NL was 
27.7%, indicating that approximately 1 in 3 adults was obese (BMI ≥ 30 kg/m2). In ten 
years, between 2000/1 and 2011, the prevalence of overweight increased from 38.2% to 
41.8% and the prevalence of obesity increased from 21.7% to 27.7% (Twells et al., 2014). 
This increase in the prevalence of obesity in the province was accompanied by an 
increase in all three classes of obesity between 2000/1 and 2011 from 16.1% to 20.5% for 
obese class I, 4.1% to 4.6% for obese class II, and 1.5% to 2.6% for obese class III 
(Twells et al., 2014). The most alarming prediction in the study by Twells and colleagues 
is that by 2019 an estimated 71% of the adult population in NL will be overweight or 
obese and increases in the prevalence of all obese classes are predicted. 
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2.2 Obesity: Etiology & Health Risk 
 
Obesity is a disease in which excess body fat has accumulated to the extent that 
health may be adversely affected and can be viewed, conceptually, as the physical 
manifestation of chronic excess energy (Sharma & Padwal, 2010; WHO Consultation on 
Obesity, 2000). The etiology of obesity is complex and multifactorial and results from a 
range of etiologies that promote long-term positive energy balance (Lau et al., 2007; 
Sharma & Padwal, 2010). The relationship between body weight, energy intake and 
expenditure can be illustrated by a simple equation: 
Energyintake – Energyexpenditure = Δ Body Weight 
Multiple factors such as diet, metabolism, and physical activity contribute to an 
individual’s energy intake and expenditure, and a change in any of these factors, if not 
corrected, will result in a net imbalance of energy, which, if positive, will lead to weight 
gain (Sharma & Padwal, 2010). An individual’s metabolic rate, or resting energy 
expenditure, is influenced by their age, gender, sarcopenia, neuroendocrine function, 
metabolically active fat, previous weight loss, and medication use (Sharma & Padwal, 
2010). Increased energy intake by over-eating may be influenced by socio-cultural 
factors, mindless eating, a lack of knowledge about healthy eating, food availability, 
emotional over-eating, certain psychiatric disorders, sleep deprivation, and medication 
use (Sharma & Padwal, 2010). Physical inactivity is also a risk factor for weight gain and 
is influenced by socio-cultural factors, musculoskeletal pain, injury, psychiatric disorders, 
and medication use (Sharma & Padwal, 2010). Lifestyle interventions, such as the 
modification of diet and physical activity, remain the main course of treatment for 
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obesity; but, adherence is poor and results in modest long-term success (Lau et al., 2007). 
Pharmacotherapy and bariatric surgery in adjunct with lifestyle interventions have been 
proven to improve health outcomes of overweight and obese individuals (Lau et al., 
2007).  
 Obesity is a major risk factor for the development of many health disorders such 
as hypertension, T2DM, cardiovascular disease, osteoarthritis, sleep apnea, certain 
cancers, and premature mortality (Picot et al., 2009). Obesity has also been shown to 
negatively impact mental, emotional, and psychosocial health (WHO Consultation on 
Obesity, 2000). Non-fatal but debilitating health problems associated with obesity 
include: respiratory difficulties, chronic musculoskeletal problems, infertility, and skin 
problems (WHO Consultation on Obesity, 2000). 
The severity of obesity health related risk varies with body weight. Underweight, 
overweight, and obesity in adults is classified by BMI which is defined as an individual’s 
weight in kilograms divided by the square of their height in metres (kg/m2) (WHO 
Consultation on Obesity, 2000). The severity of health risk increases with BMI and is 
illustrated in Table 2.1. A prospective study by Calle et al. (1999) showed that the 
association between BMI and health risk follows a U-shaped curve with those who were 
severely underweight or obese being at an increased relative risk of death from all causes.  
The relative risk of death for obese persons was more than twice of that for persons with 
BMIs in the normal weight range. This is further supported by results from a national 
longitudinal study of Canadian adults which found a significant increased risk of 
mortality in individuals who were underweight (relative risk (RR)=1.73, 95% confidence 
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interval (CI) 1.25-2.39, p<0.001) or in obese Class II or higher (RR=1.36, 95% CI, 1.00-
1.85, p<0.05) (Orpana et al., 2009). It is important to note that BMI is not the only factor 
influencing the adverse health consequences of obesity; other factors include the location 
of body fat, the magnitude of weight gain during adulthood, and a sedentary lifestyle 
(WHO Consultation on Obesity, 2000). 
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Table 2.1 
 
BMI Classification for Adults and Associated Risk of Comorbidities 
BMI (kg/m2) Health Canada 
Classification* 
Risk of Comorbidities** 
< 18.5 Underweight Low (increased risk of 
other clinical problems) 
18.5 – 24.9 Normal Weight Average 
25.0 – 29.9 Overweight Increased 
30.0-34.9 Obese Class I Moderate 
35.0 – 39.9 Obese Class II Severe 
≥ 40.0 Obese Class III Very Severe 
Note: *Health Canada, 2003, **WHO Consultation on Obesity, 2000 
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2.3 Epidemiology of Prediabetes & Type 2 Diabetes Mellitus 
 
 2.3.1 Global Trends in T2DM. Diabetes imposes high human, social, and 
economic costs on countries at all income levels and is considered to be one of the fastest 
growing epidemics in history (IDF, 2013; Zimmet & Alberti, 2012). The prevalence of 
diabetes is increasing globally mainly as a result of the rising rates of obesity but also due 
to the declining mortality of people living with diabetes (Anvari, 2014). Worldwide it is 
estimated that there are 382 million adults or 8.3% of the adult population living with 
diabetes and this number is expected to increase 55% by 2035 (IDF, 2013). Furthermore, 
an estimated 316 million adults (6.9%) have prediabetes, a number that is expected to 
climb as high as 471 million (8.0%) by the year 2035 (IDF, 2013). The economic burden 
of diabetes is enormous with 548 billion USD or 11% of the total health spending 
worldwide spent on diabetes care in 2013 (IDF, 2013). The International Diabetes 
Federation (IDF) (2013) estimates that 80% of the world’s affected population live in 
low- and middle-income countries where diabetes rates are growing at a fast pace, 
providing a worrying indication of the future impact of this disease as a major threat to 
global development. 
 Different regions of the world are affected to different degrees by diabetes. The 
smallest diabetes population is seen in Africa and the largest in the Western Pacific. 
South and Central America are expected to see the population of people living with 
diabetes increase by 60% by 2035 with the largest increase expected to be seen in Africa 
(109%) followed closely by the region of Middle East and North Africa (96%). The 
smallest increase is projected for Europe at a percent change of 22% by 2035. As a result 
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of rapid development there has been a fast-growing epidemic of diabetes in South-East 
Asia which now accounts for close to 20% of all cases of diabetes worldwide. Of the 
seven IDF regions, North America and the Caribbean ranks fifth for the number of people 
living with diabetes and this number is expected to increase by 37% by 2035 (IDF, 2013).  
 2.3.2 T2DM in Canada. Diabetes is one of the most common chronic diseases in 
Canada. In 2008/9, 8.7% of Canadians over the age of 20 were living with diabetes, 
representing 1 in 11 Canadians [Public Health Agency of Canada (PHAC), 2011], and it 
is estimated that 90% of these cases are T2DM (Anvari, 2014). In a ten year period from 
1998/9 to 2008/9, the prevalence of diabetes among all Canadians increased by 70%, 
from 3.3% to 5.6%, with the prevalence over time being consistently higher in males than 
in females (PHAC, 2011). However, the prevalence of diabetes across Canada varies by 
province and territory. After accounting for differences in age, the lowest prevalence was 
seen in Nunavut and Alberta at 4.4% and 4.9%, respectively while the highest were in 
Nova Scotia and Newfoundland and Labrador at 6.1% and 6.5%, respectively (PHAC, 
2011). These prevalence rates represent known cases of T2DM and likely underestimate 
the true prevalence as T2DM is typically present for 5 to 10 years before diagnosis. 
 One of the contributing factors to the increase in the number of Canadians living 
with diabetes is the aging population, largely a result of the baby boom cohort (PHAC, 
2011). The increased lifespan of people living with diabetes has also contributed to the 
growing prevalence rates of diabetes in the country (PHAC, 2011). However, while the 
proportion of people living with diabetes generally increases with age, more than 50% of 
the affected Canadian population is between the ages of 25 and 64 years (PHAC, 2011). 
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The proportion of individuals living with diabetes has increased more in younger age 
groups than in older age groups likely due to increasing rates of overweight and obesity 
(PHAC, 2011; Lau et al., 2007). 
 2.3.3 T2DM in Newfoundland and Labrador. NL has the highest prevalence of 
diabetes in Canada with 9.3% of the population living with diagnosed diabetes (CDA, 
2010a). The CDA estimates that the prevalence of diabetes in this province will increase 
by 56% from 2010 to 2020 (CDA, 2010a). As the prevalence of diabetes increases in NL 
so will the economic effects on the healthcare system. The economic burden of diabetes 
in NL is estimated to increase by 27% from $254 million CDN to $322 million CDN by 
the year 2020 (CDA, 2010b). The population of NL has a higher risk for diabetes than 
other provinces in Canada for many reasons: NL has the oldest population, the highest 
rates for overweight and obesity, the highest prediabetes rate, and close to the lowest 
median family income (CDA, 2010a).  
2.4 Prediabetes & Type 2 Diabetes Mellitus: Diagnostic Criteria, Etiology, & Health 
Risk.  
Diabetes is a chronic metabolic disorder that occurs when the pancreas cannot 
produce enough insulin or the body is unable to use insulin effectively. In T2DM, the 
body is able to produce insulin but either in insufficient amounts or the body is unable to 
respond to its effects, known as insulin resistance, leading to a build-up of glucose in the 
blood known as hyperglycemia (Goldenberg & Punthakee, 2013; IDF, 2013). Prediabetes 
is a term that refers to an intermediate group of individuals with glucose levels that are 
elevated from normal but not enough to meet the criteria for T2DM; these individuals are 
living with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both 
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(ADA, 2013; Goldenberg & Punthakee, 2013). Individuals living with prediabetes are at 
an increased risk of developing T2DM as well as cardiovascular disease (ADA, 2013). 
However, it is important to note that not everyone living with prediabetes will go on to 
develop T2DM, and there is a large body of evidence which supports the effectiveness of 
lifestyle interventions such as a healthy diet and physical activity to prevent the 
progression of prediabetes to diabetes (IDF, 2013).  
In 2013, the CDA released updated Clinical Practice Guidelines outlining the 
diagnostic criteria for prediabetes and T2DM which is presented in Table 2.2 and Table 
2.3, respectively. The inclusion of glycated haemoglobin (A1c) in the diagnostic criteria 
for prediabetes and T2DM is new to the 2013 Clinical Practice Guidelines.  
People living with T2DM can remain undiagnosed for many years, unaware of the 
long-term damage being caused by the disease (IDF, 2013). Often diagnosis occurs only 
when complications of the disease have already developed (IDF, 2013). While the reasons 
for developing T2DM are still unknown, there are known risk factors which include: 
obesity, poor diet, physical inactivity, aging, family history of diabetes, and ethnicity 
(Aboriginal, Hispanic, South Asian, Asian, or African descent) (CDA, 2013; IDF, 2013). 
Anyone over the age of 40 is at risk for developing T2DM and it is recommended that 
screening be done every 3 years (CDA, 2013; IDF, 2013). 
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Table 2.2 
 
Diagnostic Criteria for Prediabetes* 
Test Result Prediabetes Category 
FPG (mmol/L) 6.1 – 6.9 IFG 
2hPG in a 75g OGTT (mmol/L) 7.8 – 11.0 IGT 
A1c (%) 6.0 – 6.4 Prediabetes 
Note: 2hPG= 2 Hour Plasma Glucose, A1c= Glycated Hemoglobin, FPG= Fasting Plasma 
Glucose, IFG= Impaired Fasting Glucose, IGT= Impaired Glucose Tolerance, OGTT= 
Oral Glucose Tolerance Test  
*Goldenberg & Punthakee, 2013 
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Table 2.3 
 
Diagnostic Criteria for Type 2 Diabetes Mellitus* 
FPG ≥ 7.0 mmol/L 
 
or 
 
A1c ≥ 6.5% (in adults) 
 
or 
 
2hPG in a 75g OGTT ≥ 11.1 mmol/L 
 
or 
 
Random PG ≥ 11.1 mmol/L 
Note: 2hPG= 2 Hour Plasma Glucose, A1c= Glycated Hemoglobin, FPG= Fasting Plasma 
Glucose, OGTT= Oral Glucose Tolerance Test, PG= Plasma Glucose  
*Goldenberg & Punthakee, 2013 
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The main pathophysiological factors contributing to the onset of T2DM are 
insulin resistance and β-cell dysfunction (Taylor, 2013). Whole-body insulin resistance is 
the earliest predictor of T2DM with the earliest detection of insulin resistance found in 
skeletal muscle (Taylor, 2013). Insulin resistance may be caused by an insulin signalling 
defect, a glucose transporter defect, or lipotoxicity (Taylor, 2013). In contrast, β-cell 
dysfunction resulting in changes in insulin secretion determines the onset of 
hyperglycemia as well as the progression towards insulin-based therapy (Taylor, 2013). It 
is suggested that β-cell dysfunction may be caused by amyloid deposition in the islets, 
oxidative stress, excess fatty acid, or lack of incretin effect (Taylor, 2013). Excess fat 
inhibits β-cell functioning and there is now clear evidence that weight loss reverses β-cell 
defects at least early in the course of T2DM (Taylor, 2013).  
Furthermore, an accumulation of fat in the liver may also increase an individual’s 
risk of developing T2DM (Taylor, 2013). Storage of fat in the liver occurs only when 
there is an overall energy imbalance, i.e., when daily caloric intake exceeds energy 
expenditure (Taylor, 2013). Decreasing the amount of fat stored in the liver has been 
associated with an improvement in insulin suppression of glucose production resulting in 
an improvement of FPG (Taylor, 2013). An overall energy imbalance leads to excess fat 
in the pancreas as well as in the liver, which promotes the development of T2DM (Taylor, 
2013); however, it also leads to individuals being overweight or obese which may explain 
why the majority of patients with T2DM are overweight or obese. Abdominal fat is of 
particular concern as it promotes the secretion of inflammatory chemicals from adipose 
cells, which disrupts the ability of insulin responsive cells to respond to insulin thus 
25 
 
promoting insulin resistance and triggering the development of T2DM (Diabetes UK, 
2014). 
The development of prediabetes and T2DM is also characterized by impaired 
actions of the incretin hormones, specifically GIP and GLP-1. Recent studies suggest that 
impaired incretin effects are an early sign of impaired glucose metabolism with further 
impairment occurring as glucose intolerance develops (Opinto et al, 2013). Incretins are 
gastrointestinal hormones that stimulate a decrease in blood glucose levels by causing the 
β-cells in the pancreas to secrete insulin (Opinto et al., 2013). These hormones also 
regulate postprandial glucose disposal through the inhibition of glucagon secretion and 
delayed gastric emptying (Opinto et al., 2013). GIP is insulinotropic and its secretion in 
diabetic patients is near normal, however, its effect on insulin secretion in the presence of 
T2DM is severely impaired (Holst et al., 2009). Glucagon is a peptide hormone produced 
by α-cells in the pancreas that promotes the conversion of glycogen to glucose in the liver 
thus increasing blood glucose levels. Diabetic patients experience hyperglucagonemia as 
well as an increased glucagon response following a meal (Holst et al., 2009). One 
important antidiabetic action of GLP-1 is the inhibition of glucagon production, limiting 
the conversion of glycogen to glucose in the liver (Nauck et al., 2002). While GLP-1 
secretion is impaired in diabetic patients, the potency of its effect on insulin secretion and 
glucagon-suppression is decreased in diabetic patients compared to healthy subjects. 
These changes in GIP action and GLP-1 secretion and action cause blood glucose levels 
to be elevated from normal (Holst et al., 2009).  
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The rate of gastric emptying and the secretion and action of the incretin hormones 
are major determinants of postprandial glycemia (Marathe et al., 2013). While rates of 
gastric emptying vary within individuals, patients with diabetes frequently experience 
abnormally delayed gastric emptying, or gastroparesis (Marathe et al., 2013). 
Postprandially, the magnitude of the incretin effect is dependent on the rate of gastric 
emptying, i.e., the incretin effect should be greater in a person whose stomach empties at 
a rate of 4 kcal/min compared to a rate of 2 kcal/min (Marathe et al., 2013); thus, the 
incretin effect is impaired in diabetic patients with gastroparesis. In individuals with 
T2DM the magnitude of the GLP-1 response is crucial as the insulinotropic effects of GIP 
are reduced (Marathe et al., 2013). Furthermore, GLP-1 has an inhibitory effect on 
appetite and food intake (Holst et al., 2009); however, with the impaired incretin effects 
that accompany T2DM the effects of GLP-1 in promoting satiety are lessened and may 
help explain why many patients with T2DM are overweight or obese (Gutzwiller et al., 
1999).  
Obese subjects with normal glucose tolerance have been reported to experience a 
reduced incretin effect potentially increasing their risk for the development of prediabetes 
and T2DM (Opinto et al., 2013). Following a mixed meal and glucose ingestion, the 
secretion of GLP-1, but not of GIP, is reduced in obese subjects and there is evidence 
indicating the existence of an inverse relationship between body weight and levels of 
GLP-1 (Opinto et al., 2013). In patients living with T2DM the loss of these incretin 
effects is more extensive in obese than in lean patients (Opinto et al., 2013). 
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Fasting lipid panel levels may also be indicative of T2DM. The most common 
lipid pattern in people living with T2DM consists of elevated levels of triglycerides, low 
levels of high-density lipoprotein cholesterol (HDL), and relatively normal concentrations 
of low-density lipoprotein cholesterol (LDL) and is often referred to as diabetic 
dyslipidemia (Ginsberg et al., 2005; Mancini et al., 2013). There is substantial evidence 
supporting a key role for insulin resistance as a central pathophysiological feature of 
T2DM in the development of diabetic dyslipidemia (Ginsberg et al., 2005). A common 
characteristic of insulin resistance dyslipidemia is increased postprandial hyperlipidemia 
and, while clearance of postprandial triglycerides is usually reduced, an increased 
production of triglyceride carrying molecules, chylomicron particles, may also play a role 
(Ginsberg et al., 2005). Thus, as T2DM improves, or remission is achieved, and insulin 
resistance decreases, there should be an improvement in triglyceride serum levels. 
People living with diabetes are at risk of developing a number of serious health 
problems. Diabetes is considered a leading cause of blindness, end-stage renal failure, and 
lower limb amputations as well as a major risk factor for cardiovascular disease (Dixon et 
al., 2005; Doggrell & Chan, 2012; IDF, 2013; Maggio & Pi-Sunyer, 2003). Though there 
are many treatments available for T2DM, more than 60% of individuals living with 
T2DM die from heart disease or stroke (Doggrell & Chan, 2012). In 2013, 5.1 million 
deaths worldwide were attributed to diabetes and this number is expected to increase 
significantly as a result of the rise in the global prevalence of diabetes (IDF, 2013). 
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2.5 Obesity & Type 2 Diabetes Mellitus 
 
 The relationship between obesity and T2DM is undisputable and is further 
established by the fact that the prevalence of both are increasing in parallel (Anvari, 
2014). The term “diabesity” has been coined to demonstrate the close link between these 
chronic conditions (Dixon et al., 2005).  
Overweight, and especially visceral adiposity, are important risk factors for the 
development of T2DM and its complications and are considered to be the driving force 
behind the rising prevalence of T2DM. It is estimated that 80% to 90% of T2DM cases 
can be attributed to overweight and obesity (Abbatini et al., 2012; Wharton et al., 2013). 
Historically, T2DM has been considered a disease of the aged with most patients being 
diagnosed after the age of 40 years; however, in recent years there has been an emergence 
of T2DM diagnoses among overweight and obese adolescents and youth highlighting the 
serious health consequences of obesity on all age groups (Maggio & Pi-Sunyer, 2003; 
PHAC, 2011).  
A study from the United States estimates that, at birth, the risk of developing 
diabetes is 1 in 3; however, this risk can be modified by weight and BMI (Narayan et al., 
2007). Narayan and colleagues (2007) further investigated the impact of BMI on the 
lifetime risk of diabetes and discovered that in males 18 years of age the lifetime risk of 
developing diabetes for those with BMI < 18.5 kg/m2 was 7.6% compared to 70.3% for 
those with BMI > 35 kg/m2. A similar result was seen in females whose lifetime risk of 
diabetes ranged from 12.2% to 74.4% for BMIs <18.5 kg/m2 and > 35 kg/m2, respectively 
(Narayan et al., 2007). The results for males and females at 65 years of age were similar 
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but not as dramatic as those for individuals 18 years of age. In males 65 years of age the 
remaining lifetime risk of developing diabetes ranged from 2.2% to 34.7% for BMIs 
<18.5 kg/m2 and > 35 kg/m2, respectively (Narayan et al., 2007). In females 65 years of 
age the lifetime risk of developing diabetes for those with BMI < 18.5 kg/m2 was 3.7% 
compared to 36.0% for those with BMI > 35 kg/m2 (Narayan et al., 2007). The study 
concluded that compared to individuals with a lower BMI, individuals living with obesity 
(BMI ≥ 30 kg/m2) have a higher risk of developing diabetes, having the disease for a 
longer period of time, and excess life-years lost to diabetes (Narayan et al., 2007).  
Results from the Nurses’ Health Study which observed more than 84,000 female 
nurses further support the idea that the risk of developing T2DM increases with BMI. The 
study’s findings suggested the risk of developing T2DM increased 20-fold for those in 
obese class I (30.0 kg/m2 ≤ BMI ≤ 34.9 kg/m2) and 38-fold for those in obese classes II 
and III (BMI ≥ 35 kg/m2) (Maggio & Pi-Sunyer, 2003). The Nurses’ Health Study also 
reported that increasing BMI, increasing weight gain, weight gain after the age of 18 
years, and duration of obesity are all positively associated with the development of T2DM 
(Maggio & Pi-Sunyer, 2003). From the perspective of excess body weight, it is estimated 
that for each kilogram increase in measured weight the risk of diabetes increases by 4.5% 
(Maggio & Pi-Sunyer, 2003). 
Not only is obesity a risk factor for the development of T2DM but it also has an 
impact on the disease when both coexist. Obesity increases insulin resistance and glucose 
intolerance and heightens metabolic abnormalities associated with T2DM such as 
hyperinsulinemia, hyperglycemia, and dyslipidemia thus complicating the management of 
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T2DM and making it more difficult to treat pharmacologically (Maggio & Pi-Sunyer, 
2003). Furthermore, intensive insulin therapy and some antidiabetic medications such as 
sulfonylureas and thiazolidinediones promote weight gain which further complicates the 
management of T2DM in obese patients (Maggio & Pi-Sunyer, 2003; Wharton et al., 
2013). 
2.6 Weight Management in Prediabetes & Type 2 Diabetes Mellitus 
 
 Obesity is a major risk factor for the development of prediabetes and T2DM and 
causes further complications with these chronic conditions; thus, weight management is 
an extremely important aspect in the treatment of prediabetes and T2DM. A modest 
weight loss of 5% to 10% can substantially improve glycemic control (Wharton et al., 
2013) and can potentially prevent the succession from prediabetes to T2DM by almost 
60% (Ransom et al., 2013). Weight loss improves glycemic control by increasing insulin 
sensitivity and glucose uptake and diminishing hepatic glucose output (Maggio & Pi-
Sunyer, 2003; Wharton et al., 2013). Weight loss in patients living with obesity and 
T2DM also improves existing comorbidities such as dyslipidemia and hypertension 
(Maggio & Pi-Sunyer, 2003; Wharton et al., 2013). It follows that the CDA Clinical 
Practice Guidelines (2013) recommend an interdisciplinary weight management program 
along with adjunctive pharmacotherapy, if necessary, for overweight and obese people 
with, or at risk for, T2DM to prevent weight gain and to achieve and maintain a lower, 
healthy body weight (Wharton et al., 2013).  
However, people living with T2DM often have difficulty losing weight due in part 
to insulin resistance and also to the side effects of weight gain associated with some 
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antidiabetic medications and insulin therapies (Lau et al., 2007). The clinical practice 
guidelines recommend that adults with T2DM and either class II or class III obesity may 
be considered for bariatric surgery when lifestyle interventions are inadequate in 
achieving healthy weight goals (Wharton et al., 2013). 
2.7 Bariatric Surgery 
 
Bariatric (weight loss) surgery is the only intervention proven to promote 
significant, sustainable weight loss and sustained improvement in weight-related 
comorbidities in individuals living with obesity (Jackson & Hutter, 2012; Mechanick et 
al., 2013). Currently there are approximately five bariatric procedures available in Canada 
and an increasing population of eligible candidates. When lifestyle interventions are 
unsuccessful in achieving healthy weight goals, patients may be recommended for 
bariatric surgery based on the following eligibility criteria: BMI ≥ 35 kg/m2 with 
comorbidities or BMI ≥ 40 kg/m2 (Lau et al., 2007). 
The primary bariatric procedures recommended to be performed in patients 
requiring weight loss are laparoscopic adjustable gastric banding (LAGB), LSG, 
laparoscopic Roux-en-Y gastric bypass (LRYGB), and laparoscopic biliopancreatic 
diversion (BPD), BPD/duodenal switch (BPD-DS), or related procedures (Mechanick et 
al., 2013). All bariatric procedures fundamentally involve altering the digestive system in 
either a restrictive, malabsorptive, or a combination of restrictive/malabsorptive capacity 
to induce rapid, sustainable weight loss (Belle et al., 2007; Padwal et al., 2011; Picot et 
al., 2009). Bariatric procedures that are considered to be restrictive such as LSG and 
LAGB, physically limit the amount of food, and thereby calories, that an individual can 
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consume by reducing gastric volume. Malabsorptive procedures restrict nutrient 
absorption in the small intestine and include BPD and BPD-DS. LRYGB is an example of 
a bariatric procedure that uses both restriction and malabsorption to help patients lose 
weight.  
In 2011, there were 340,768 bariatric procedures performed worldwide with the 
majority (101,645) being performed in the USA/Canada (Buchwald & Oien, 2013). The 
most commonly performed procedures worldwide are Roux-en-Y gastric bypass (RYGB) 
(46.6%), sleeve gastrectomy (27.8%), and adjustable gastric banding (17.8%) (Buchwald 
& Oien, 2013) with more than 90% of bariatric surgeries performed laparoscopically 
through small incision ports in the abdomen (Padwal et al., 2011). It is interesting to note 
the dramatic increase in popularity of LSG as a bariatric procedure. Buchwald and 
Williams (2004) reported that LSG accounted for 0% of bariatric surgeries performed 
worldwide in 2003 and just 8 years later an updated report published by Buchwald and 
Oien (2013) estimated that LSG accounted for 27.8% of bariatric surgical procedures 
performed worldwide in 2011. Despite these astonishing figures, it is noted that only 1% 
of the eligible population receives surgical treatment for obesity (Mechanick et al., 2013). 
In NL, LSG is the most common surgical treatment option for obesity. First 
described in 1988, LSG began as the first stage of a 2-stage procedure in superobese high-
risk patients to induce weight loss and lower their operative risk before undergoing a 
more complicated procedure such as BPD-DS or RYGB (Behrens et al., 2011; Victorzon 
2012). Since 1993, LSG has been performed as a stand-alone bariatric procedure 
demonstrating benefits comparable to other procedures (Mechanick et al., 2013; 
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Victorzon 2012). In the USA, a national risk-adjusted database placed LSG between 
LRYGB and LAGB in terms of weight loss, resolution of comorbidities, and 
complications (Mechanick et al., 2013). It follows that LSG is no longer considered to be 
investigational and is currently recommended as a primary bariatric procedure by the 
American Society for Metabolic and Bariatric Surgery (Mechanick et al., 2013). The 
surgical procedure involves resecting the greater curvature and fundus of the stomach, 
leaving a tube or a “sleeve” with a volume of 60-100 mL (Behrens et al., 2011; Gill et al., 
2010; Padwal et al., 2011).  
Weight loss following LSG is attributed to a reduced stomach volume leading to 
decreased food intake but also to decreases in gastrointestinal hormone levels such as 
serum ghrelin, a major hunger-inducing hormone (Behrens et al., 2011; Padwal et al., 
2011). With respect to incretins, LSG has been shown to increase the post-prandial 
release of distal gut hormones, namely GIP and GLP-1, to a similar extent as seen 
following RYGB (Romero et al., 2012). The exact mechanism by which LSG creates 
favorable weight loss and metabolic changes is not yet fully understood. 
A recent systematic review performed by Victorzon (2012) noted that the 
quantity, quality, and consistency of evidence concerning LSG for the treatment of severe 
obesity is low. Numerous studies following patients for one to three years post-LSG have 
shown good results for weight loss; however, there is a lack of long-term published data 
available for a follow-up of ≥ 5 years with at least 100 patients. There is a similar gap in 
long-term data surrounding LSG and its impact on the resolution of comorbidities, 
particularly T2DM. Several small retrospective studies reported an effect on rates of 
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T2DM remission at four months to three years following LSG (Abbatini et al., 2010; 
Cassella et al., 2011; Chouillard et al., 2011; Kehagias et al., 2011; Lee et al., 2011; 
Nocca et al., 2011; Rosenthal et al., 2009; Vidal et al., 2007; Woelnerhanssen et al., 
2011). If future long-term studies report weight loss, resolution of comorbidities, and 
quality of life improvements comparable to the more popular LRYGB, LSG may surpass 
LRYGB as the bariatric procedure of choice due to its increased simplicity and reduced 
risk of nutrient deficiencies and surgical risks. 
2.7.1 Bariatric Surgery in Newfoundland and Labrador. In May of 2011 the 
Eastern Health Regional Health Authority of NL introduced LSG as a surgical treatment 
option for severe obesity. A bariatric surgery clinic, including two bariatric surgeons, a 
nurse practitioner, and a dietician was established to provide 70-100 LSG surgeries 
annually. In December 2012, a third bariatric surgeon was recruited and the estimated 
number of surgeries performed per year is 100. 
2.7.2 Bariatric Surgery & Improvement or Remission of T2DM. Although the 
aim and success of weight loss interventions such as bariatric surgery are often based on 
the amount of weight lost, improvements in quality of life and comorbidities are generally 
a more meaningful indication of success for individuals. In the long term, weight loss 
from surgical interventions is associated with decreased risk of developing T2DM, 
resolution of T2DM, and a reduction in LDL-cholesterol, total cholesterol, and blood 
pressure as well as reduced mortality in patient deaths resulting from T2DM, heart 
disease, and cancer (Picot et al., 2009; Poirier et al., 2011). Of particular interest is the 
effect of bariatric surgery on preventing T2DM and remission of pre-existing T2DM. 
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Many studies have examined the effect of bariatric surgery on T2DM and while all types 
of bariatric surgery have been associated with remission of T2DM, malabsorptive 
procedures appear to be the most effective (Poirier et al., 2011). Both the ADA and CDA 
recommend bariatric surgery for obese individuals (BMI ≥ 35 kg/m2) living with T2DM 
as a viable treatment option for their diabetes (ADA, 2013; Wharton et al., 2013). Small 
trials have shown the glycemic benefits of bariatric surgery in patients living with T2DM 
and BMIs of 30-35 kg/m2 who normally would not be eligible for surgery (ADA, 2013). 
However, neither the ADA nor the CDA recommend surgery in this patient population as 
current evidence is limited by the number of subjects studied and the lack of long-term 
data demonstrating net benefit (ADA, 2013; Mechanick et al., 2013; Wharton et al., 
2013).  
2.7.3 Effects of LSG vs. LAGB & RYGB on Improvement or Remission of 
T2DM. It is well known that bariatric surgery is the most effective treatment for severe 
obesity but evidence is emerging to suggest that it may also be effective in inducing 
remission of T2DM, with the results varying by the type of operation. Often this effect 
occurs before significant amounts of weight are lost; thus, it is thought to be a result of 
changes in gut hormones and diet. Numerous studies have examined the effects of LSG, 
LAGB, and LRYGB independently on the improvement or remission of T2DM but fewer 
studies have directly compared the effects of LSG versus either LAGB or LRYGB. Two 
meta-analyses, one comparing LSG to LAGB and the other comparing LSG to LRYGB, 
were published in 2013 and are critically appraised below. 
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2.7.3.1 Wang et al. (2013). The purpose of this meta-analysis by Wang and 
colleagues (2013) was to compare the effects of LSG and LAGB on %EWL and T2DM. 
Searches for relevant publications from 2000 to 2012 were carried out via PubMed and 
Embase with the final search being conducted in August of 2012. Inclusion and exclusion 
criteria were well defined and a total of 11 studies consisting of a combined total of 1,004 
patients were included in the meta-analysis. The included studies were a mixture of 
randomized and non-randomized studies. Of the 1,004 patients, 616 underwent LAGB 
and 388 underwent LSG. The length of follow-up in the studies included ranged from 6 to 
12 months. Statistical heterogeneity was tested by the chi-square test and according to the 
forest plots, heterogeneity was limited and the Mantel-Haenszel fixed effect model was 
used. 
The results of the meta-analysis indicated that LSG had a greater effect than 
LAGB on %EWL and was superior in treating T2DM at 6 and 12 months post-surgery. 
Five studies reported 42 of 68 patients (61.8%) living with T2DM experienced 
improvement of their diabetes after LAGB compared to 66 of 80 (82.5%) patients living 
with T2DM who improved following LSG. The authors concluded that LSG was a more 
effective procedure than LAGB, with a pooled odds ratio of 0.34 (95% CI 0.16-0.73). 
One common limitation in meta-analyses is publication bias. While the authors 
produced a series of funnel plots to assess the publication bias of the literature it remains 
that searches were not inclusive of unpublished data, conference abstracts, or studies not 
in the English language. Secondly, there were a small number of studies included in the 
analysis, some of which had low sample sizes which may have biased the results. Also, 
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the papers included that studied LSG lack long-term results, with most reporting on 6 and 
12 month data. Perhaps the most limiting factor of this meta-analysis is that the definition 
of improvement or remission of T2DM is not clearly stated in the paper. It is 
recommended that larger, randomized, long-term follow-up studies be conducted to 
compare the efficacy of LSG, LAGB, and LRYGB. 
2.7.3.2 Li et al. (2013). The aim of this meta-analysis of randomized controlled 
trials (RCT) was to compare the efficacy of LRYGB and LSG in treating morbid obesity 
or T2DM. Searches for relevant RCTs in any language, published between 1966 and 2012 
were carried out via Cochrane Central Registrar of Controlled Trials, Medline, Embase, 
ISI databases, and the Chinese Biomedical Literature Database. The authors had well-
defined inclusion and exclusion criteria and a total of 5 RCTs were selected for inclusion 
in the meta-analysis. The quality of the included studies was assessed using the Jadad 
composite scale (range 0 to 5) which assesses randomization, blinding, and dropouts and 
all studies scored 4 or higher. These 5 RCTs encompassed a total of 396 patients; 196 
patients in the LRYGB group and 200 in the LSG group. The length of follow-up in the 
studies ranged from 1 to 36 months with the majority (3) of the studies reporting a 12 
month follow-up period. Remission of T2DM was defined as FPG levels less than 126 
mg/dL (7.0 mmol/L) and A1c levels less than 6.5% without the use of antidiabetic 
medications. The studies were homogenous with respect to clinical and methodological 
criteria and the chi-square test statistic was used to assess any heterogeneity among the 
studies. Summary estimates were calculated using a fixed-effects model. 
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The results showed that the patients who underwent LRYGB lost more weight, 
had a higher remission rate of T2DM (OR 9.08, 95% CI 2.39-34.41, p=0.001), and had 
lower LDL, triglycerides, and insulin levels than those in the LSG group. Based on these 
results the authors concluded that LRYGB is more effective than LSG for the surgical 
treatment of T2DM; however, LSG is safer and has a lower rate of complications 
following surgery. It is also noted that LRYGB excludes the duodenum leading to long-
term micronutrient deficiency in patients however this is avoided in LSG patients as that 
procedure does not exclude the duodenum. The authors recommend that in order to 
provide more reliable evidence, more high-quality RCTs with longer-term follow-up 
periods must be conducted. 
One strength of this study was that the outcome measure for remission of T2DM 
was clearly defined by the authors. In terms of limitations, this meta-analysis was 
primarily limited by the lack of RCTs with large sample sizes and long-term follow-up. 
Small sample sizes could be the reason that the 95% CI (2.39-34.41) was so wide for the 
difference in the rate of remission of T2DM between patients who underwent LRYGB 
and LSG. Lack of long-term follow-up makes it almost impossible to comment on the 
durability of remission of T2DM post-surgery and the possibility of weight re-gain in the 
future. 
2.7.4 LSG & Remission of T2DM. Current research indicates that while LRYGB 
appears to be a more efficacious procedure than LSG with respect to weight loss and 
T2DM remission, it is a much more complex surgical procedure associated with 
significant morbidity postoperatively (Gill et al., 2010; Li et al., 2013). LSG has been 
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reported to promote weight loss and improve T2DM remission rates; however, while 
meta-analytic techniques involving a large number of studies have been identified in the 
literature exploring the effectiveness of LSG in the setting of T2DM, the individual 
studies have small, heterogeneous patient populations (Gill et al., 2010; Li et al., 2013; 
Wang et al., 2013). A systematic review was conducted by Gill et al. in 2010 to review 
the effect of LSG on T2DM. The information from this systematic review has been 
combined with data from studies published between 2010 and 2014 with the baseline 
demographics presented in Table 2.4 and the results with respect to weight loss and 
T2DM remission presented in Table 2.5. A critical appraisal of this systematic review is 
presented below. 
2.7.4.1 Gill et al. (2010). This study was carried out with the intention of 
systematically reviewing the existing literature on the efficacy of LSG for weight loss and 
the remission of T2DM. Studies between the years 2000 and April 2010 were identified 
using electronic databases such as MEDLINE, PubMed, Embase, Scopus, Dare, Clinical 
Evidence, BIOSIS Previews, TRIP, Health Technology Database, Cochrane Library, 
conference abstracts, and clinical trials. The authors also took into consideration 
unpublished and non-English language studies in an effort to reduce publication bias. 
Based on the inclusion criteria, 27 studies reporting data on a total of 673 patients were 
chosen to be included in the systematic review. Remission of T2DM was defined as 
discontinuation of all antidiabetic medications and normal FPG levels, normal 
postprandial glucose excursions, and normal A1c. The high heterogeneity among the 
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studies and a lack of RCTs deemed a meta-analysis to be inappropriate. Follow-up time in 
the studies ranged from 3-36 months with a mean follow-up time of 13.1 months. 
Of the 27 included studies, 26 included the primary outcome of T2DM remission. 
Remission rates ranged from 14% to 100% with 20 studies reporting remission rates of 
T2DM ≥ 50%. A total of 19 studies also reported improvements in T2DM with the 
improvement rates ranging from 2% to 86%. It is still unknown if the LSG induced 
improvement in T2DM will translate into a long-term decrease in patient mortality. 
At the time of the systematic review, no RCTs had been published assessing the 
remission of T2DM following LSG. However, the authors conducted a comprehensive 
review of the available literature and assessed the articles for methodologic quality using 
the Cochrane (concealment of allocation) and risk of bias tools. There are numerous 
potential sources of bias inherent in non-randomized studies, thus the results of this 
systematic review should be interpreted with caution. The authors indicate a need for the 
development of high-level randomized clinical trial evidence on this issue. 
Based on the results, the authors concluded that LSG has a substantial effect on 
T2DM with most patients experiencing remission of T2DM following surgery. The 
authors promoted LSG as a promising surgical procedure for the treatment of obesity and 
T2DM.  
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Table 2.4 
 
Baseline Characteristics of Studies Included in the Systematic Review* and Recent Studies** 
Investigator Patients  
(n) 
Mean Age  
(years) 
Gender 
(% Female) 
Mean BMI 
(kg/m2) 
Follow-up period 
(months) 
Sieber et al., 2014** 68 43.1 78 43.0 ± 8.0 60 
Perathoner et al., 2013** 93 46 (median) 73 44.1 ± 6.9 17.4 (mean) 
Desiderio et al., 2013** 15 58.8 67 37.9 ± 1.5 12 
Rawlins et al., 2013** 49 44 70 65 60 
Abbatini et al., 2013** 26 49.3 70 52.1 ± 8.5 36 
Slater et al., 2011** 22 55.3 21 46 12 
Lakdawala et al., 2010* 7    12  
Lirosi et al., 2010* 34  68 53 ± 8 3 
Nienhuijs et al., 2010* 20 42  51 12 
Sammour, et al., 2010* 25    12 
Shah et al., 2010* 53 46.5 ± 8.7 55 45.2 ± 9.3 12 
Todkar et al., 2010* 23 44.6 ±11.9 74 40.7 ± 6.6 36 
Basso et al., 2009* 20 46.6 ± 4.2 60  51.6 ± 16 36 
Berry et al., 2009* 14 50.6 ± 12.7 64 38.3 ± 6.7 6 
Chowbey et al., 2009* 23    6 
Frezza et al., 2009* 53 51 79 53.5 18 
Jacobs et al., 2009* 39    12 
Keidar et al., 2009* 18    3 
Letessier et al., 2009* 18    14 
Magee et al., 2009*     12 
Nocca, 2009* 33   50.6 12 
Rosenthal et al., 2009* 30 42.3 70 46.1 ± 11 6 
Cottam et al., 2006* 75    12 
Gan et al., 2007* 21  62 52.8 ± 8.2 11.4 
Kasalicky et al., 2008* 17    18 
Lee et al., 2008* 20 46.3 70 31 ± 2.9 12 
Ou Yang et al., 2008* 33   50.6 ± 11 24 
Tagaya et al., 2008* 6    12 
Vidal et al., 2008* 39 49.9 ± 1.5 59 51.9 ± 1.2 12 
Wheeler et al., 2008* 13    3.4 
Weiner et al., 2007* 14    12 
Moon Han et al., 2005* 8    6 
Silecchia et al., 2005* 17    18 
Note: BMI= Body Mass Index, PCS= Prospective Clinical Study, RCS= Retrospective Clinical Study, RCT= Randomized Clinical Trial. 
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Table 2.5 
 
Laparoscopic Sleeve Gastrectomy Outcomes for Studies Included in the Systematic Review* and Recent Studies** 
Investigator Glucose level  
(mmol/L) 
A1c (%) %EWL T2DM (%) 
 Pre Post Pre Post Change (%)  Resolved Improved Stable 
Sieber et al., 2014**       85   
Perathoner et al., 2013**   5.9 5.4 -0.45 55.7 85   
Desiderio et al., 2013** 9.91 6.26 8.1 5.6 -2.5 58.4 40 33.3 26.7 
Rawlins et al., 2013**      86.0 100   
Abbatini et al., 2013** 7.95 4.91 7.3 5.5 -1.8  85   
Slater et al., 2011**   7.4 6.1 -1.3 56 75 25  
Lakdawala et al., 2010*       98 2  
Lirosi et al., 2010*      6.3 85 15  
Nienhuijs et al., 2010*      49.6 50 40 10 
Sammour, et al., 2010*       48 24 7 
Shah et al., 2010*   8.4 6.1 -2.3  96.2 3.8  
Todkar et al., 2010* 8.74 5.38 9.1 6.4 -2.7 74.6 69.6  30.4 
Basso et al., 2009*   7.7 5.9 -1.8 36.3 80.9   
Berry et al., 2009* 7.33 5.37 7.1 5.5 -1.6  85.7 14.3  
Chowbey et al., 2009*   6.46 5.2 -1.26  82.6 17.4  
Frezza et al., 2009*  6.55    59.2    
Jacobs et al., 2009*       82 18  
Keidar et al., 2009*       77   
Letessier et al., 2009*       41.2 47.1  
Magee et al., 2009*       23   
Nocca, 2009*      60.1 75.8 15.2  
Rosenthal et al., 2009* 8.82 7.12 6.4 5.9 -0.5 35.4 63.3 36.7  
Cottam et al., 2006*      46 81 11  
Gan et al., 2007* 8.09 5.79 8 6.6 -1.4 35.9 14 81 5 
Kasalicky et al., 2008*       71 29  
Lee et al., 2008* 13.33 7.38 10.1 7.1 -3.0 70.4 50   
Ou Yang et al., 2008*   7.91 6.47 -1.44 46.1 39   
Tagaya et al., 2008*       67 33  
Vidal et al., 2008* 14.03 8.72 7.4 6.9 -0.5  84.6   
Wheeler et al., 2008*     -2.2  61.5   
Weiner et al., 2007*       14 86  
Moon Han et al., 2005*       100   
Silecchia et al., 2005*       79.6 15.4  
Note: %EWL= Percent Excess Weight Loss, A1c= Glycated Hemoglobin, T2DM= Type 2 Diabetes Mellitus; case definitions of remission and improvement vary
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2.7.5 How Does LSG Work? Conventionally, it is thought that weight loss and 
remission of T2DM following LSG results directly from gastric and caloric restriction 
after anatomically reducing the size of the stomach. However, there is growing evidence 
to suggest that these mechanisms are not the primary driving force behind metabolic 
improvements post-surgery. Below are some proposed mechanisms of weight loss and 
T2DM remission following LSG. 
One hypothesis that is gaining popularity is that weight loss and metabolic 
improvements after LSG occur following changes in gut physiology leading to changes in 
hormone production, for example, ghrelin and peptide-YY (PYY). Ghrelin is produced by 
endocrine cells in the fundus of the stomach and functions to increase appetite and 
promote gastric emptying and intestinal mobility inducing feelings of hunger (Xanthakos, 
2008). A study by Langer et al. (2005) reported that ghrelin levels following LSG were 
reduced as early as one day post-surgery and ghrelin levels remained low and stable at 1 
and 6 months follow-up which is likely due to the resecting of the fundus of the stomach 
during LSG. Thus, patients have less appetite for food and a longer-lasting sensation of 
fullness leading to decreased food intake and weight loss following LSG. A second 
hormone, PYY also plays an important role in weight loss. PYY is produced in the distal 
ileum and colon and has a hunger-reducing effect (Wang et al., 2013; Xanthakos, 2008). 
Research indicates that postprandial PYY levels increase following LSG which further 
increases the weight loss effects of LSG (Karamanakos et al., 2008). It may be that the 
combination of reduced gastric volume and hormonal changes seen after LSG contribute 
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to the greater weight loss achieved following LSG compared to LAGB (Wang et al., 
2013).  
With respect to improvements in T2DM it is believed that by countering insulin 
resistance brought on by severe obesity with increased insulin sensitivity, improved 
control of T2DM can be achieved (Wang et al., 2013). Any bariatric procedure which 
induces weight loss will increase insulin sensitivity and thereby improve T2DM; 
however, it is still uncertain if weight loss is the major contributor to improvement of 
T2DM following LSG.  
Incretins such as GLP-1 and GIP also play an important role in the improvement 
of T2DM and weight loss. GLP-1 is secreted in the ileum and colon and increases 
pancreatic secretion of insulin in response to oral glucose ingestion to decrease serum 
levels of glucose. It is thought that GLP-1 increases following LSG which further helps to 
ameliorate T2DM (Wang et al., 2013). The hormonal changes that occur paired with the 
weight loss induced by LSG may be the contributing factors to the remission of T2DM 
post-surgery. 
Given that a substantial number of patients living with T2DM are no longer taking 
antidiabetic medications within days after bariatric surgery and before substantial weight 
loss has occurred, new hypotheses are emerging to try and explain this phenomenon. 
Recently, a paper published by Ryan et al. (2014) hypothesized that the effects of LSG on 
weight loss and improved glucose control were related to bile acids. In addition to aiding 
mechanical digestion and absorption of lipids, bile acids regulate metabolism by binding 
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to the nuclear receptor farsenoid-X receptor (FXR). LSG is one bariatric procedure that is 
associated with significantly higher levels of circulating total bile salts in human and 
rodent models. The authors examined the effects of LSG on mice with diet-induced 
obesity and targeted genetic disruption of FXR. In this study, LSG was associated with a 
20% decrease in fasting blood glucose and substantial improvements in glucose tolerance 
in unaltered mice whereas mice with genetic disruption of FXR experienced an increase 
of 24% in fasting blood glucose levels and exhibited no changes in glucose tolerance 
post-surgery. These results indicate that in the absence of the nuclear receptor FXR, the 
ability of LSG to reduce body weight and improve glucose tolerance is reduced 
substantially.  
Furthermore, FXR was shown to alter feeding behaviors following LSG (Ryan et 
al., 2014). When given the choice between three diets, mice with no disruption in FXR 
that underwent LSG exhibited a preference for dietary carbohydrates and protein relative 
to dietary fat and maintained a lower food intake for up to 3 weeks, neither of which was 
the case in mice with genetic disruption of FXR (Ryan et al., 2014). This indicates that 
increased levels of bile salts, along with natural changes in dietary preferences may be 
responsible for weight loss and comorbid resolution following LSG.  
However, the physiology of bile acids is different between mice and humans so 
caution should be exerted when translating these results to humans (Kuipers & Groen, 
2014). This finding by Ryan et al. (2014) should encourage future studies to try and 
explain the mechanism by which FXR influences the metabolic effects of LSG and 
comparable procedures in humans (Kuipers & Groen, 2014). 
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While many hypotheses exist, the exact mechanism by which LSG induces weight 
loss and metabolic improvements is still uncertain. With LSG being a relatively new 
procedure compared to other bariatric surgeries, more studies are necessary to determine 
the exact mechanism or combination of mechanisms that work together to provide the 
weight loss and metabolic benefits following this procedure. 
2.7.6 Remission of Type 2 Diabetes Mellitus: Definition & Predictors. With 
the concepts of “remission” and “cure” of T2DM following bariatric surgery gaining 
acceptance, it is necessary to define what these terms mean in the case of diabetes. 
Improved or normalized glycemic levels are obvious factors to be considered but is it 
appropriate to use the term remission or cure for all patients with normal glycemic 
measures irrespective of how this is achieved? In 2009, a consensus group comprised of 
experts in pediatric and adult endocrinology, diabetes education, transplantation, 
metabolism, bariatric/metabolic surgery, and hematology-oncology was formed to discuss 
this issue. For a chronic disease such as diabetes, it is more appropriate to use the term 
remission rather than cure due to the likelihood that any current or potential treatments for 
T2DM will likely leave patients at risk for relapse as a result of underlying 
pathophysiologic abnormalities and/or genetic predisposition to the disease. The 
consensus group agreed upon using various stages of remission in their definition of 
remission of diabetes (Table 2.6). It is also noted that the specific (microvascular) or 
nonspecific (cardiovascular) complications patients can experience as a result of living 
with diabetes will likely need ongoing monitoring indefinitely even if a patient achieves 
prolonged remission of diabetes (Buse et al., 2009). 
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Table 2.6 
Summary of Consensus Group Definitions of Remission of Type 2 Diabetes Mellitus* 
Partial Remission 
Glycemic measures above normal but  below diagnostic thresholds for T2DM 
At least 1 year’s duration 
No active pharmacologic therapy 
Complete Remission 
Normal glycemic measures 
At least 1 year’s duration 
No active pharmacologic therapy 
Prolonged Remission 
Complete remission of at least 5 years’ duration 
*Buse et al., 2009 
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Research has been conducted to determine if there are any preoperative prognostic 
factors that can be used to predict the likelihood of a patient achieving remission of 
T2DM following bariatric surgery. A study by Casella et al. (2011) looked specifically at 
ten-year duration of T2DM as a prognostic factor for remission following sleeve 
gastrectomy. The study reported that the duration of T2DM was an important prognostic 
factor with patients living with T2DM for less than 10 years experiencing 100% 
remission while those patients living with T2DM for more than 10 years experiencing 
significantly lower rates of remission. Robert et al. (2013) conducted a study aimed at 
identifying predictive factors of T2DM remission one year after bariatric surgery and 
found that baseline BMI < 50 kg/m2, duration of T2DM ≤ 4 years, A1c ≤ 7.1%, FPG < 
6.3 mmol/L, and absence of insulin therapy were predictors of remission of T2DM. 
Research carried out by Still et al. (2013) aimed to create a score to predict remission of 
T2DM which took into account preoperative insulin use, age, A1c concentration, and type 
of antidiabetic drugs being used in predicting the likelihood of a patient achieving 
remission of T2DM post-surgery with the greatest weight given to insulin use before 
surgery. A final study conducted by Lee et al. (2013) reported that operative methods, 
waist circumference, and C-peptide levels were significant predictors for the remission of 
T2DM following bariatric surgery. These four studies report a variety of potential 
prognostic factors that can predict a patient’s likelihood of achieving remission of T2DM. 
More research on this topic is necessary to determine which of these factors are the best 
predictors of remission and which factors are of the most importance before it is possible 
to use this information as a means of recommending candidates for surgery to achieve 
remission of T2DM.  
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The above factors that are mentioned as being predictive of remission of T2DM 
following bariatric surgery are indicators of decreases in pancreatic islet cell reserve. 
Declining islet cell function begins as early as 12 years prior to diagnosis of T2DM with 
the acute insulin response decreasing by 27% during the progression from normal to 
impaired to glucose tolerance, and by 51% during the transition from IGT to T2DM 
(Fonseca, 2009). This helps explain duration of diabetes, age, blood glucose levels, and 
insulin use as potential predictors of remission of T2DM. The remaining predictive factor, 
C-peptide level, is a direct measure of islet cell reserve as C-peptide is cleaved from 
proinsulin in order to release mature insulin; thus, low levels of C-peptide in diabetic 
patients are indicative of decreased islet cell function or reserve (Wahren et al., 2000).  
Research is not only focused on preoperative prognostic factors of remission of 
T2DM following bariatric surgery but also on the prevention of T2DM following surgery. 
A study by Carlsson et al. (2012) investigated the effect of bariatric surgery on the 
prevention of T2DM. This nonrandomized, prospective, controlled study included 3429 
patients; 1658 patients underwent bariatric surgery and 1771 obese matched controls. 
After a 15 year follow-up period, T2DM developed in 392 patients in the control group 
and in 110 bariatric surgery patients. The corresponding incidence rates of T2DM were 
28.4 cases per 1000 person-years for the control group and 6.8 cases per 1000 person-
years for the surgery group (adjusted hazard ratio with bariatric surgery, 0.17, 95% CI 
0.13-0.21, p<0.001). The effect of bariatric surgery on incident T2DM was influenced by 
the presence or absence of IFG but not by BMI. The authors concluded that bariatric 
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surgery was markedly more efficient than usual care in the prevention of T2DM in obese 
persons. 
2.8 Summary of Gaps in the Clinical Literature 
 
 A review of the clinical literature revealed several gaps that exist in current 
knowledge related to bariatric surgery and the improvement or remission of T2DM. 
Firstly, there are very limited data available on outcomes following LSG from a Canadian 
health care perspective. Secondly, none of the studies explored the effects of bariatric 
surgery on the improvement of glycemic control in patients living with prediabetes. 
Prediabetes is a major risk factor for the development of T2DM, thus if bariatric surgery 
is successful in ameliorating prediabetes then the incidence of future diabetes in this at-
risk population will decrease. Finally, despite the fact that in 2009 Buse and colleagues 
released guidelines specifically outlining definitions of remission for T2DM there is still 
major heterogeneity amongst existing studies when defining T2DM remission. These 
gaps in the literature provided the basis of the present research and helped guide the 
development of the research questions. 
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Chapter 3: Methods 
 
 This chapter outlines the study population and sample, procedure, definitions of 
the outcomes of interest, data analysis, and ethical considerations.  A standardized data 
abstraction form was used to collect the following information: patient demographics 
such as age, gender, employment status, level of education, history of comorbid 
conditions, etc.; weight, height; blood glucose levels, cholesterol, triglycerides, blood 
pressure; and medication use. The statistical data analysis plan used to answer the 
research questions and ethical considerations are also discussed. This research was 
conducted using a prospective, inception cohort study design. 
3.1 Population and Sample 
 
 The eligible population for this inception cohort study was all individuals who 
underwent LSG in NL between May 2011 and September 2013 and consented to 
participate in the NL BaSco Study. This time period was chosen so that, at the time of 
analysis, all patients included in the analysis would have been eligible for at least a six 
month follow-up appointment. The sample consisted of patients who, before undergoing 
surgery, met the following inclusion criteria: (a) based on laboratory results met the 
requirements for a case diagnosis of prediabetes, FPG level of 6.1 mmol/L - 6.9 mmol/L 
or A1c level of 6.0% – 6.4% (Goldenberg & Punthakee, 2013); or (b) based on laboratory 
results, met the requirements for a case diagnosis of T2DM, FPG ≥ 7.0 mmol/L or A1c ≥ 
6.5% (Goldenberg & Punthakee, 2013); and/or (c) a self-reported history of impaired 
fasting glucose or diabetes, or were taking antidiabetic medications at baseline. The 
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antidiabetic medications included in this study are biguanide (metformin), sulfonylureas 
(gliclazide, glyburide), alpha glucosidase inhibitor (acarbose), dipeptidyl-peptidase-4 
(DPP-4) -inhibitors (saxagliptin, sitagliptin), meglitinides (repaglinide, nateglinide), 
thiazolidines (pioglitazone, rosiglitazone), glucagon-like-peptide-1 (GLP-1) receptor 
aganosits (liraglutide), rapid-acting insulin (insulin lispro, insulin aspart), fast-acting 
insulin (regular insulin), intermediate-acting insulin (insulin NPH), and long-acting 
insulin (insulin glargine, insulin detemir).  
At the end of September 2013, 171 individuals had undergone LSG. Of these 
patients, 24 (14.0%) were defined as having prediabetes and 67 (39.2%) were defined as 
having T2DM before undergoing surgery. 
3.2 Procedure 
 
 For this study, data was collected from the time surgery began in the province in 
May 2011 until March 2014 (i.e., during the pre-admission process and at various time 
intervals after surgery). Patients were referred by their family physician to the provincial 
bariatric surgery program housed in the Health Sciences Center at Eastern Health, the 
province’s tertiary care center, where the bariatric nurse practitioner performed a 
preliminary eligibility screening of patients and invited eligible patients to a pre-surgical 
education session. Information regarding the surgical procedure, the importance of 
nutrition, and how to read food product labels was provided at this session. Patients were 
encouraged to start a food journal and initiate a daily multivitamin regime. Following the 
education session, interested patients met with the bariatric nurse practitioner and a 
detailed medical history was taken. Once deemed eligible for surgery, patients were 
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informed of the research study by a member of the clinical team and permission was 
requested for a research nurse coordinator to meet with them to provide more 
information. The research nurse gave each potential participant a detailed explanation of 
the study, an introductory letter addressed from the researcher and a consent form at their 
initial clinic visit with the nurse practitioner. Permission was obtained to meet again after 
their scheduled appointment with the surgeon to review the research project after the 
potential participant had at least 24 to 48 hours to review the materials. Once the surgeon 
gave final approval for LSG and obtained written surgical consent, the research nurse met 
with the potential participant to answer any questions and obtain informed written consent 
to participate in the cohort study.  
Baseline data was collected after informed consent was given. For this analysis, 
172 patients were approached by the research nurse to participate in the study and 171 
agreed to participate giving a response rate of 99.4%. For the purposes of the current 
thesis, the sample size is n=171. A diagram outlining the pre-surgical process for patients 
from the time of referral to the date of surgery is presented in Figure 3.1. 
 Laboratory assessments were completed throughout the province but the majority 
of the biochemical assessments were performed at the Health Sciences Centre in St. 
John’s. The methods and equipment used to perform the biochemical assessments were 
obtained through personal correspondence with Dr. Edward Randell, Division Chief, 
Department of Laboratory Medicine, Eastern Health. The analysis for FPG, triglycerides, 
HDL, and cholesterol were performed on the Architect c8000 and c16000 clinical 
chemistry systems by Abbott Diagnostics. A1c values were analyzed on a G8 HbA1c 
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analyzer (Tosoh) by HPLC. Values of LDL were calculated using the Friedewald 
equation. In all cases, the necessary testing reagents came from the same vendors as listed 
above. 
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Figure 3.1. The pre-surgical process for patients from referral for bariatric surgery 
to undergoing laparoscopic sleeve gastrectomy. 
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After consenting to participate in the study, patients filled out a series of 
questionnaires to collect information on socio-demographics, health services use, and 
quality of life. For one week prior to surgery, patients were required to follow a full-fluid 
diet. This diet was fully outlined for the patients by the dietician and the daily 
recommendations were as follows: fluid intake of 2-3 litres for females or 3-4 litres for 
males, protein supplements of 60-80 grams, calorie intake of 800-1200 kcal, and an adult 
multivitamin-mineral supplement. Patients recorded their daily food intake during the 
week which was later reviewed by the dietician. The full fluid diet was resumed again 
after surgery for a period of 4 weeks after which soft foods were re-introduced into the 
diet followed by solid foods 8 weeks post-surgery. As part of clinical standards of care 
and following the full fluid diet, patients had standard blood work completed at the pre-
admission clinic. Patients’ official pre-surgery weight, blood pressure, heart rate, and 
waist circumference, and medication use were also recorded at the pre-admission clinic. 
 Follow-up appointments took place at 1, 3, 6, and 12 months post-surgery. The 1 
month appointment was a clinic visit with the bariatric nurse practitioner where 
anthropometric measures, blood pressure, heart rate, and medication use was recorded. At 
every other follow-up appointment, blood work was required to be completed and 
medication use recorded. Questionnaires regarding health services use and quality of life 
were re-administered at 6 and 12 months post-surgery.  
3.3 Defining Primary Outcome Measures of Prediabetes & T2DM 
 
 Following data entry, it was necessary to determine if, at baseline, patients had 
normal glucose tolerance, type 1 diabetes, prediabetes, or T2DM; the latter two being the 
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focus of the current research study. Depending on the relationship that a patient has with 
their family physician, the patient may or may not have regular blood testing done. It is 
for this reason that we could not fully rely on a patient’s self-reported medical history to 
determine if they were prediabetic or had T2DM. The process of identifying prediabetic 
or T2DM patients is outlined in sections 3.3.1 and 3.3.2, respectively and begins with 
examining the results from the laboratory testing. Patients with FPG and A1c levels in the 
normal range, with no reported history of IFG, diabetes, or antidiabetic medication use 
were considered to have normal glucose tolerance. Patients with type 1 diabetes (n=1) 
were identified by the bariatric nurse practitioner on the medical history form and 
recorded appropriately in the database and were not included in the current analysis.  
3.3.1 Prediabetes. Prediabetes, as outlined in Chapter 2, is defined as FPG levels 
ranging from 6.1–6.9 mmol/L and A1c levels from 6.0–6.4%. Thus, the first step in 
identifying prediabetic patients was to examine their blood glucose levels. Any patient 
with FPG and/or A1c levels within this range was further investigated. The next step was 
to consider the patient’s medication use. If the patient was not taking medication for 
diabetes s(he) was coded as prediabetic. If the patient was taking antidiabetic medications 
the medication dose was taken into consideration. In 2 cases where it was uncertain 
whether or not the patient was prediabetic or had T2DM another member of the research 
team with expertise in endocrinology was consulted (CK). 
3.3.2 T2DM. The case definition of T2DM is FPG ≥ 7.0 mmol/L or A1c ≥ 6.5% 
thus, any patient with glucose levels above these thresholds was considered to have 
T2DM. Other patients whose diabetes was medically managed were identified through 
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their medication use profile as well as their self-reported medical history. Patients’ 
glycemic control and medication use was re-evaluated at 3, 6, and 12 months post-
surgery. Only medication use was recorded at the 1 month appointment. No laboratory 
testing was completed at that time. 
3.3.3 Case Definitions of Improvement and Remission of Prediabetes and 
T2DM. Case definitions of improvement or remission of prediabetes and T2DM were 
created based on the recommendations by Buse et al. (2009) and are presented in Table 
3.1 and Table 3.2, respectively. Definitions take into consideration glycemic levels (i.e., 
FPG, A1c) as well as any changes in the use of antidiabetic medications post-surgery. 
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Table 3.1 
 
Case Definitions of Improvement and Remission of Prediabetes 
Improvement 
Lower glycemic measures 
At least 1 year’s duration 
Pharmacologic therapy required but at a lower dose 
Normalization 
Normal glycemic measures 
At least 1 year’s duration 
Pharmacologic therapy required but at a lower dose 
Remission 
Normal glycemic measures 
At least 1 year’s duration 
No active pharmacologic therapy 
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Table 3.2 
 
Case Definitions of Improvement and Remission of Type 2 Diabetes Mellitus* 
Improvement 
Hyperglycemia below diagnostic thresholds for T2DM 
At least 1 year’s duration 
Pharmacologic therapy required but at a lower dose 
Partial Remission 
Hyperglycemia below diagnostic thresholds for T2DM 
At least 1 year’s duration 
No active pharmacologic therapy 
Complete Remission 
Normal glycemic measures 
At least 1 year’s duration 
No active pharmacologic therapy 
*Buse et al., 2009 
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3.4 Data Analysis 
 
 Data was entered into Statistical Package for the Social Sciences (SPSS) version 
20.0 (IBM Corp., Armonk, NY) for analysis. Data quality assurance was carried out using 
descriptive statistics and frequencies. There were no apparent errors related to data entry 
and no outliers were identified. This research is part of a larger study that is using a 
prospective cohort design to assess short-term outcomes (e.g., weight loss, 
improvement/remission of T2DM, health care use and costs) in patients undergoing LSG.  
 3.4.1. Baseline Demographics. Descriptive statistics were used to create a profile 
of participants’ personal characteristics, anthropometric measures at baseline, 
comorbidity status, biochemical parameters, and medication use. Based on the inclusion 
criteria, the percentage of patients with prediabetes or T2DM was also calculated. 
 3.4.2. Analysis of the Primary Outcomes. The primary outcomes for this study 
were the determination of the proportions of patients experiencing improvement or 
remission of prediabetes or T2DM as well as if any changes occured in FPG or A1c levels 
12 months following LSG. The proportion of patients that achieved remission of 
prediabetes or T2DM 12 months after surgery were reported as frequencies and 
percentages based on the case definitions presented in Tables 3.1 and 3.2, respectively.  
 To determine if any changes in FPG and A1c levels were statistically significant, 
data were analyzed using Generalized Estimating Equation (GEE) regression models. 
GEEs represent an extension of the generalized linear model of continuous, ordinal, 
polychotomous, dichotomous, and count-dependent data which are designed to 
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accommodate for correlations between repeated measures (Twisk, 2003). Data for FPG 
and A1c levels were collected at baseline and at three time points post-surgery (3, 6, and 
12 months) making this data repeated measures. It was inappropriate to conduct repeated 
measures ANOVA analysis on this data as many patients were missing information at 
various time points and would thus be excluded from the statistical analysis. GEE was 
used so that all patients could be included in the statistical analysis as this method does 
not assume that there is complete information for every patient and adjusts for 
correlations between measurements which exist in this data as they are repeated 
measures. The model used a normal linear link function, had a normal outcome 
distribution, and an exchangeable correlation structure. Time was included as a factor in 
the model and baseline values were used as the comparator in order to assess if there was 
a statistical difference in changes of FPG and A1c levels at 3, 6, and 12 months post-
surgery. Statistical significance was set at p<0.05 using the Wald chi-square test carried 
out in the GEE analysis. 
 3.4.3 Analysis of the Secondary Outcomes. The analysis of the secondary 
outcomes focused on the examination of any associations between baseline factors, or 
change in weight 12 months post-surgery and remission of prediabetes or T2DM. 
Changes that occurred in weight and other variables including blood pressure, fasting 
lipid panel levels and triglycerides, and dose and number of antidiabetic medications 
prescribed 12 months post-surgery were also investigated. 
The strength and direction of relationships between baseline factors or change in 
weight and remission of prediabetes or T2DM were established through the use of the 
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Pearson product moment correlation (Pearon's r) or its non-parametric equivalent 
Spearman's rho when determining the correlation between two continuous variables or 
Fisher’s exact test when determining the association between two categorical variables. 
The variables chosen to be included in the analysis were based on the baseline 
information collected from patients and previously published research examining 
predictors of remission of T2DM following bariatric surgery.  
Based on previously published research, baseline BMI, pre-operative insulin use 
(Robert et al., 2013), and age (Still et al., 2013) were chosen to be included in the 
univariate association analysis. Baseline weight was included as it has been thought to 
potentially be indicative of remission of diabetes (Lee et al., 2013). Levels of triglycerides 
were included as decreases in triglyceride levels can often be predictive of improvements 
in insulin resistance (Ginsberg et al., 2005); thus, if triglyceride levels decreased post-
surgery it would be interesting to see if these changes were associated with remission of 
T2DM. Sex was included to explore whether or not females were more likely to 
experience remission of T2DM than males or vice versa. Finally, self-reported medical 
histories of hypertension, dyslipidemia, and in the T2DM cohort chronic renal disorder, 
were chosen because these are common comorbidities associated with diabetes and may 
be indicative of more advanced diabetes in a patient; thus, it was interesting to see if 
patients with or without these conditions were more likely to achieve remission of 
prediabetes or T2DM 12 months post-surgery.  
Averages of weight, blood pressure, fasting lipid panel levels and triglycerides 
were calculated at baseline and at 3, 6, and 12 months post-surgery. Changes in these 
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variables were calculated as differences between the pre- and post-surgery values. 
Statistical significance of any changes in these values was determined using GEE as was 
done for the primary outcome. The model was set-up in an identical manner for each of 
these outcomes.  
 Percent excess weight loss (%EWL) is defined as the percentage of excess weight 
a patient loses post-surgery and was calculated based on the equation: %EWL = (initial 
weight – weight at follow-up) ÷ (initial weight – ideal body weight) x 100 (Picot et al., 
2009). Ideal body weight was determined using the mean of the medium frame ideal body 
weights for men and women based on height from the 1983 Metropolitan Height and 
Weight Tables (1983 metropolitan height and weight tables, 1983). An equation to 
illustrate the concept of %EWL is provided: a female patient with a height of 5’3” and 
weight of 240 lbs has a BMI of 42.7. She would have an ideal BMI of 25 if she weighed 
140 lbs meaning she carries 100 lbs of excess weight. Following LSG, she can expect to 
lose between 45-60% of her excess weight. Thus, post-surgery, she can expect to lose 
anywhere from 45-60 lbs putting her at a weight between 180-195 lbs.  
Percent absolute weight loss (%AWL) is defined as the percentage of initial 
weight a patient loses post-surgery. The calculation of %AWL following surgery was 
based on the equation: %AWL = (initial weight – weight at follow-up) ÷ (initial weight) x 
100. 
Antidiabetic medication and statin use were reported as frequencies at each time 
point to represent the number of patients taking each medication and the dose of 
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medication was reported as an average value. The use of statins was included to aid in the 
discussion of any changes that may have occurred in HDL, LDL, triglycerides, and total 
cholesterol post-surgery. 
3.5 Privacy & Ethical Considerations 
 
 Ethical approval and subsequent renewals for this research have been obtained 
from Memorial University’s Health Research Ethics Authority (previously the Human 
Investigation Committee, HIC# 11.101). A copy of this approval can be found in 
Appendix A. 
Patients were provided with written material describing the study and what would 
be expected of them for their own personal review before signing written, informed 
consent with the research nurse. Prior to signing consent, patients were made aware that 
they could choose to withdraw from the study at any time and were informed that all 
personal information would remain confidential and anonymous. All data was de-
identified by the research nurse and each patient was given a unique ID to ensure 
anonymity of the participants to the research staff. All data was stored in a filing cabinet 
in the Patient Research Centre and electronic versions of the databases were stored on a 
password-protected computer. Only the research nurse had access to the master list; the 
anonymous questionnaires and access to the databases was limited to the primary 
investigators and research staff. 
 Data collected by the bariatric nurse practitioner and the research nurse were 
forwarded in a de-identified manner to another member of the research team (KL) for 
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entry into the database. Once the data abstraction form was received, it was photocopied, 
coded, and the data was entered into the database. The original abstraction form was 
returned to the research nurse for storage while the copy was stored in the Patient 
Research Centre in a locked cabinet. The computer containing the databases was 
password-protected and all files were backed up to an external hard drive as they were 
updated.  
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Chapter 4: Results 
 
 The following chapter presents the results of the study in 6 sections. The first 
section describes the demographic profile of the sample as well as for the prediabetes and 
T2DM cohorts including weight measures, comorbidity profile, and socio-demographic 
characteristics and laboratory measures. The second and third sections present the results 
for the prediabetes and T2DM cohorts, respectively including the proportion of patients 
that achieved improvement or remission of prediabetes as well as changes in glycemic 
measures post-surgery. The fourth section examines if there are any pre-operative factors 
that may be associated with the remission of prediabetes or T2DM following LSG. The 
fifth section examines if weight loss 12 months post-surgery was associated with changes 
in glycemic measures, triglycerides, fasting lipid panels, or remission of prediabetes or 
T2DM. The sixth section presents the results for the secondary research questions 
including changes in weight, BMI, blood pressure, and serum levels of triglycerides and 
cholesterol, and antidiabetic medication use post-surgery. It also presents changes in the 
use of statins post-surgery for the T2DM cohort. As previously noted, this research is part 
of a larger study that is using a prospective cohort design to assess short-term outcomes 
(e.g., weight loss, improvement/resolution of diabetes, health care use and costs) in 
patients undergoing LSG; thus, the analysis is based on a sample of patients from the 
population enrolled in the NL BaSco Study. 
4.1 Baseline Demographics, Comorbidity Profile, & Laboratory Values 
 
 Of the 171 patients who had undergone LSG by the end of September 2013, 91 
(53.2%) met the case definition for either prediabetes or T2DM. Figure 4.1 details the 
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number of patients included the study and breaks down the prediabetes and T2DM 
cohorts to show the number of patients returning at each follow-up period. The baseline 
characteristics are presented in Table 4.1. The study sample was predominantly female 
(76.9%) with an average age of 45.6 ± 10.4 years. The average weight was 135.6 ± 23.9 
kg corresponding to an average BMI of 48.6 ± 7.1 kg/m2. The average blood pressure 
before surgery was 130/80 ± 13/10 mmHg. The majority of the sample was Caucasian 
(90.1%) and either married or living in a common-law relationship (71.4%). The majority 
of the sample (64.8%) had received post-secondary education. Prior to surgery, in 
conjunction with the bariatric nurse practitioner, patients self-reported their medical 
history. The most commonly reported comorbidities were hypertension (67.8%), diabetes 
(62.8%), sleep apnea (61.6%), and dyslipidemia (60.5%). 
 Based on the case definitions outlined in Chapter 3, 24 patients (26.4%) were 
identified as prediabetic and 67 patients were identified as having T2DM (73.6%). Of the 
67 patients identified as being diabetic 54 patients (80.6%) had a self-reported history of 
diabetes. Table 4.1 highlights the socio-demographic and anthropometric measures for 
each of these cohorts, as well as a detailed comorbidity profile. The cohorts do not differ 
significantly (p<0.05) in age, weight, BMI, blood pressure, or any of the socio-
demographic factors. The proportions of patients in the T2DM cohort reporting a history 
of diabetes, dyslipidemia, or polycystic ovarian syndrome were statistically significantly 
(p<0.05) higher than the proportions of patients in the prediabetes cohort. 
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Figure 4.1. Patients who had undergone LSG by the end of September 2013 divided into prediabetes and T2DM cohorts 
and their attendance of follow-up appointments. f/u=follow-up, LSG=laparoscopic sleeve gastrectomy, T2DM = type 2 
diabetes mellitus
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Table 4.1 
 
Baseline Demographics 
Characteristic 
Mean ± SD 
All Patients 
(n=91) 
Prediabetes 
(n=24) 
T2DM 
(n=67) 
Age, years 45.6 ± 10.4 46 ± 11.0 
126.6 ± 22.9 
46.7 ± 7.1 
 
131 ± 12 
83 ± 9 
45 ± 10.4 
138.8 ± 23.6 
49.3 ± 7.0 
 
129 ± 14 
79 ± 10 
Weight, kg 135.6 ± 23.9 
BMI, kg/m2 48.6 ± 7.1 
Blood Pressure, mm Hg  
Systolic 130 ± 13 
Diastolic 80 ± 10 
 n % n % n % 
Female 70 76.9 19 79.2 51 76.1 
Caucasian 82 90.1 20 83.3 62 92.5 
Married/Common-Law 65 71.4 16 66.7 49 73.1 
Level of Education       
High School 14 15.4 6 25.0 8 11.9 
College Diploma 40 43.9 8 33.3 32 47.8 
University Degree 19 20.9 5 20.8 14 20.9 
Other 18 19.8 7 29.2 22 32.8 
Self-Reported Medical 
History†  
      
Hypertension 59 67.8 15 68.2 44 67.7 
Diabetes* 54 62.8 2 9.5 52 80.0 
Sleep Apnea 53 61.6 13 59.1 40 61.5 
Dyslipidemia* 52 60.5 9 40.9 43 67.2 
Osteoarthritis 41 47.7 10 45.5 31 47.7 
Polycystic Ovarian 
Syndrome* 
19 27.1 1 5.2 18 35.3 
Hypothyroidism 16 18.6 2 9.1 14 21.5 
Chronic Renal Disorder 8 9.3 0 0 8 12.3 
Coronary Artery Disease 7 4.2 1 4.5 6 9.2 
Cerebral Vascular Disease 3 3.4 1 4.5 2 3.1 
Congestive Heart Failure 2 1.2 1 4.5 1 1.5 
Peripheral Vascular Disease 0 0 0 0 0 0 
Note: SD=standard deviation, T2DM=type 2 diabetes mellitus  
†n=86 for entire cohort, n=22 for prediabetes cohort, n=65 for T2DM cohort 
*p<0.05 between prediabetes and T2DM cohorts  
  
71 
 
The pre-operative means for the laboratory measures of interest including 
glycemic measures (FPG, A1c), triglycerides, and fasting lipid panel are presented in 
Table 4.2. Patients in the prediabetes cohort had an average A1c of 5.9 ± 0.3% and FPG 
of 5.8 ± 0.6 mmol/L. The average A1c and FPG for those in the T2DM cohort were 7.8 ± 
1.4% and 8.5 ± 2.9 mmol/L, respectively. Average levels of triglycerides and the average 
ratios of cholesterol/HDL were higher than the reference range for both cohorts. The 
prediabetes cohort had statistically significant (p<0.05) lower levels of both A1c and FPG 
compared to the T2DM cohort whereas the T2DM cohort had statistically significant 
(p<0.05) lower levels of total cholesterol and LDL compared to the prediabetes cohort. 
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Table 4.2 
 
Baseline Laboratory Results of Patients With Prediabetes or T2DM 
 Reference 
Values 
Prediabetes† 
(n=24) 
T2DM‡ 
(n=67) 
Glycemic Measures    
A1c, % 4.0 – 6.0 5.9 ± 0.3* 7.8 ± 1.4 
FPG, mmol/L 3.5 – 6.0 5.8 ± 0.6* 8.5 ± 2.9 
    
Triglycerides, mmol/L 0.0 – 1.7 2.1 ± 0.8 2.2 ± 0.8 
    
Fasting Lipid Panel, mmol/L    
Total Cholesterol 2.5 – 6.1 5.2 ± 1.3 4.5 ± 1.1* 
HDL 0.7 – 2.0 1.1 ± 0.2 1.0 ± 0.2 
LDL 1.4 – 4.2 3.1 ± 1.0 2.6 ± 1.0* 
Ratio (Cholesterol/HDL) 0 – 4.0 4.9 ± 1.1 4.8 ± 1.4 
Note: Results presented as mean ± standard deviation; A1c=glycated hemoglobin, 
FPG=fasting plasma glucose, HDL=high density lipoprotein, LDL=low density 
lipoprotein, T2DM=type 2 diabetes mellitus  
†Case definition for prediabetes: 6.1 mmol/L ≤ FPG ≤ 6.9 mmol/L, 6.0% ≤ A1c ≤ 6.4% 
‡Case definition for T2DM: FPG ≥ 7.0 mmol/L, A1c ≥ 6.5% 
*p<0.05 when compared to the T2DM cohort 
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4.2 Prediabetes: Results 
 
 Of the 24 patients that met the case definition for prediabetes, 3 were lost to 
follow-up and failed to return for any appointments. Thus, they were not included in the 
final analysis leaving a sample of 21 patients. 
4.2.1 Proportion of Patients Achieving Improvement or Remission. Of the 21 
patients with prediabetes that were included in this analysis, 11 (52.4%) completed 
follow-up at 12 months post-surgery. The remaining patients had not yet reached 12 
month follow-up post-surgery. The case definition of normalization was normal glycemic 
levels for a period of 12 months with the use of pharmacological agents, whereas, the 
case definition for remission was normal glycemic levels for a period of 12 months 
without the use of pharmacological agents. Within the first 12 months following surgery 9 
(81.8%) patients achieved remission of prediabetes evidenced by normal glycemic 
measures and no requirement to use antidiabetic medications. The two remaining patients 
who had not yet achieved remission had normal glycemic measures for a period of 6 
months without the use of antidiabetic medications and appeared to be progressing 
towards achieving remission.  
4.2.2 Changes in Glycemic Measures. Prior to surgery and at 3, 6, and 12 
months post-surgery, blood samples were collected from patients and the results were 
forwarded to the research team. The results of the tests with respect to FPG and A1c 
levels can be found in Figure 4.2. The biggest change in glycemic measures happened 
within the first three months following surgery with FPG levels decreasing from 5.8 
mmol/L to 5.1 mmol/L and A1c decreasing from 5.9% to 5.5%. By six months post-
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surgery, the average FPG level had decreased to 5.0 mmol/L and A1c levels remained at 
5.5%. These lower levels were maintained up to 12 months post-surgery and were 
statistically significant (p<0.05) at all time points when compared to baseline levels.  
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Figure 4.2. Changes in fasting plasma glucose (FPG, mmol/L) and glycated 
hemoglobin (A1c, %) in prediabetic patients. *p<0.05 for FPG levels when compared 
to baseline. **p<0.01 for A1c levels when compared to baseline. 
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4.3 T2DM: Results 
 
 Of the 67 patients that met the case definition for T2DM, 8 were lost to follow-up 
and failed to return for any appointments. Thus they were not included in the final 
analysis leaving a sample of 59 patients. 
4.3.1 Proportion of Patients Achieving Improvement or Remission. Of the 59 
patients with T2DM that were included in this analysis, 24 (40.7%) had completed 
follow-up at 12 months post-surgery. Within the first 12 months following surgery 6 
(25%) patients achieved remission of T2DM. Of the 6 patients who achieved remission 4 
were considered to be in partial remission, as demonstrated by glycemic measures below 
the case definition for T2DM without the use of antidiabetic medications for a period of 
12 months. The remaining 2 patients were in complete remission with normal glycemic 
measures without the use of antidiabetic medications for a period of 12 months. Five 
patients (20.8%) experienced improvement of their diabetes. These patients had glycemic 
measures below the case definition for diagnosis of T2DM and required either fewer 
antidiabetic agents or lower doses of those medications to achieve lower glycemic levels. 
One point of interest is that at 12 months post-surgery, 13 patients (54.2%) had glycemic 
levels below the diagnostic thresholds identified in the case definition for T2DM and no 
longer required the use of antidiabetic medications; however, they had not yet maintained 
these levels for a period of 12 months.   
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4.3.2 Changes in Glycemic Measures. Figure 4.4 illustrates the changes in A1c 
and FPG levels post-surgery in patients identified with T2DM. Similar to the prediabetes 
cohort, the biggest change occurred within the first 3 months following surgery; average 
FPG levels decreased from 8.6 mmol/L at baseline to 6.4 mmol/L, while average A1c 
levels decreased from 7.9% to 6.3% during the first 3 months. Glycemic measures 
continued to decrease after the initial large drop within the first three months following 
surgery. By 6 months post-surgery, average FPG and A1c levels had decreased to 6.0 
mmol/L and 6.2%, respectively. By 12 months post-surgery average FPG levels were 5.6 
mmol/L and average A1c levels were 5.9% (n=24). All changes post-surgery were 
statistically significant (p<0.05) when compared to baseline levels. 
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Figure 4.3. Changes in fasting plasma glucose (FPG, mmol/L) and glycated 
hemoglobin (A1c, %) in patients with T2DM. *p<0.05 for FPG levels when compared 
to baseline. **p<0.01 for A1c levels when compared to baseline. 
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4.4 Baseline Factors Associated with Remission of Prediabetes and T2DM  
 
A series of chi-square (Fisher’s exact test) and Pearson product moment 
correlation (Pearson’s r) analyses were performed to determine if any baseline factors 
were associated with patients achieving remission of prediabetes or T2DM post-surgery. 
The baseline factors included in the analysis were age, weight, BMI, triglyceride levels, 
sex, and self-reported medical history of hypertension, dyslipidemia, and/or chronic renal 
disorder. For patients with T2DM the use of insulin pre-surgery was also analyzed. The 
continuous variables of age, weight, BMI, and triglyceride levels were analyzed using 
Pearson’s product moment bivariate correlation analysis and the dichotomous variables of 
sex, self-reported medical history, and insulin use were analyzed using chi-square tests 
specifically Fisher’s exact test. Due to the small sample sizes for the prediabetes (n=11) 
and T2DM (n=24) cohorts Fisher’s Exact Test results were reported when cells in the 2x2 
tables had expected counts less than 5. The results of the analyses for the prediabetes and 
T2DM cohorts are presented in Tables 4.3 and 4.4, respectively. 
Within the prediabetes cohort, weight was the only factor associated with 
remission following LSG. There was a strong, negative correlation between the two 
variables, r=-0.71, n=11, p=0.01. Within the T2DM cohort none of the included baseline 
factors were associated with patients achieving remission post-surgery. These results 
should be interpreted with caution because sample sizes are small, thus the number of 
patients achieving the outcome is also small, thereby making it difficult to detect 
associations that may be present.  
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Table 4.3 
 
Univariate association of selected baseline factors with remission of prediabetes 
following LSG (n=11) 
 Remission 
(n=9) 
No Remission 
(n=2) 
p-value 
Age, years 45.6 ± 9.8 58.5 ± 5.0 0.11 
Weight, kg 122.7 ± 15.3 157.0 ± 4.5 0.01 
BMI, kg/m2 45.8 ± 5.5 54.5 ± 8.2 0.09 
Triglycerides 1.8 ± 0.6 2.1 ± 0.3 0.61 
Sex (Female) 8 1 0.35 
Medical History     
Hypertension 7 1 0.38 
Dyslipidemia 3 2 0.44 
Note: LSG=laparoscopic sleeve gastrectomy. Values are presented as mean ± standard 
deviation for continuous data or as frequencies for dichotomous variables. 
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Table 4.4 
 
Univariate association of selected baseline factors with remission of T2DM following 
LSG (n=24) 
 Remission 
(n=6) 
No Remission 
(n=18) 
p-value 
Age, years 44.3 ± 4.5 49.8 ± 10.8 0.24 
Weight, kg 131.3 ± 12.6 138.4 ± 24.6 0.51 
BMI, kg/m2 49.4 ± 6.6 50.4 ± 5.7 0.71 
Triglycerides, mmol/L 2.3 ± 1.2 2.3 ± 0.8 1.0 
Sex (Female) 6 13 0.28 
Medical History    
Hypertension 3 15 0.14 
Dyslipidemia 4 15 0.27 
Chronic Renal Disorder 2 3 0.57 
Insulin Use 1 9 0.34 
Note: LSG=laparoscopic sleeve gastrectomy, T2DM=type 2 diabetes mellitus. Values are 
presented as mean ± standard deviation for continuous data or as frequencies for 
dichotomous variables. 
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4.5 Association of weight loss with changes in FPG, A1c, triglycerides, HDL, LDL, 
and total cholesterol and overall remission of prediabetes and T2DM  
 A series of Pearson’s product moment correlation analyses (Pearson’s r) were 
carried out to determine if the amount of weight loss 12 months following LSG was 
associated with changes in blood pressure or levels of FPG, A1c, triglycerides, HDL, 
LDL, or total cholesterol in prediabetic and diabetic patients. The results of the analyses 
for the prediabetic and T2DM cohorts are presented in Tables 4.5 and 4.6, respectively. 
Also, the association between weight loss and remission of prediabetes and T2DM was 
explored using Pearson’s product moment correlation (Pearson’s r) analyses. 
 At 12 months post-surgery, the 11 prediabetic patients with complete 12 month 
data achieved a weight loss of 37.1 ± 11.1 kg. This change in weight was not associated 
with changes in blood pressure or levels of FPG, A1c, triglycerides, HDL, LDL, or total 
cholesterol 12 months following LSG. Furthermore, the 12-month weight loss of 
prediabetic patients was not associated with remission of prediabetes 12 months post-
surgery (p=0.76). 
 The 24 T2DM patients with complete 12-month data achieved a weight loss of 
36.5 ± 13.4 kg 12 months post-surgery. Two factors, a decrease in FPG (-2.3 ± 2.2 
mmol/L, p<0.01) and an increase in HDL (0.2 ± 0.2 mmol/L, p=0.01) were associated 
with weight loss 12 months following LSG. There was a strong, negative correlation 
between the amount of weight lost and change in FPG, r=-0.59, n=22, p<0.01 and a 
strong, negative correlation between weight loss and change in HDL, r=-0.51, n=23, 
p=0.01, 12 months post-surgery. However, the amount of weight lost was not associated 
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with remission of T2DM 12 months after LSG (p=0.39). These results should be 
interpreted with caution because sample sizes are small, thereby making it difficult to 
detect associations that may be present. 
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Table 4.5 
 
Univariate association of changes in blood pressure and selected laboratory values with 
weight loss 12 months following LSG in prediabetic patients (n=11) 
 Change p-value 
Blood Pressure, mmHG   
Systolic -4.8 ± 12.9 0.17 
Diastolic -4.6 ± 15.1 0.36 
FPG, mmol/L -0.55 ± 0.72 0.19 
A1c, % -0.42 ± 0.26 0.67 
Triglycerides, mmol/L -0.68 ± 0.63 0.90 
HDL, mmol/L 0.35 ± 0.24 0.27 
LDL, mmol/L -0.23 ± 1.1 0.50 
Total Cholesterol, mmol/L  -0.19 ± 1.3 0.69 
Note: A1c=glycated haemoglobin, FPG=fasting plasma glucose, HDL=high-density 
lipoprotein, LDL=low-density lipoprotein, LSG=laparoscopic sleeve gastrectomy. Values 
are presented as mean ± standard deviation. 
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Table 4.6 
 
Univariate association of changes in blood pressure and selected laboratory values with 
weight loss 12 months following LSG in diabetic patients (n=24) 
 Change p-value 
Blood Pressure, mmHg   
Systolic -13.2 ± 16.3 0.47 
Diastolic -7.3 ± 11.4 0.80 
FPG, mmol/L -2.3 ± 2.2 <0.01 
A1c, % -1.7 ± 1.2 0.08 
Triglycerides, mmol/L -0.8 ± 0.9 0.15 
HDL, mmol/L 0.2 ± 0.2 0.01 
LDL, mmol/L 0.3 ± 0.9 0.89 
Total Cholesterol, mmol/L  0.2 ± 0.9 0.29 
Note: A1c=glycated haemoglobin, FPG=fasting plasma glucose, HDL=high-density 
lipoprotein, LDL=low-density lipoprotein, LSG=laparoscopic sleeve gastrectomy. Values 
are presented as mean ± standard deviation. 
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4.6 Secondary Outcomes: Changes in Weight, Blood Pressure, Triglycerides and 
Cholesterol, and Changes in Antidiabetic Medication Use  
 Changes post-surgery in weight loss measures, blood pressure, triglycerides and 
fasting lipid panel levels for both the prediabetes and T2DM cohorts are outlined in Table 
4.7. Within the first 6 months following surgery, patients in the prediabetes and T2DM 
cohorts had lost an average of 29.8 ± 9.2 kg and 29.1 ± 8.4 kg, respectively. In the 
prediabetes cohort, average BMI decreased from 46.9 ± 6.8 kg/m2 to 36.2 ± 5.3 kg/m2 
(p<0.05) at 6 months following surgery. Within the first 6 months post-surgery, patients 
with prediabetes had a %EWL of 45.2 ± 9.4% and had lost an average of 22.9 ± 4.6% of 
their initial body weight. Similar changes were seen in the cohort of patients with T2DM. 
In the first 6 months post-surgery, average BMI decreased from 49.6 ± 7.0 kg/m2 to 39.5 
± 6.0 kg/m2 (p<0.05), %EWL was 39.1 ± 10.0%, and patients had lost on average 20.8 ± 
4.6% of their initial body weight. Changes in weight and BMI post-surgery were 
statistically significant (p<0.05) for both cohorts at all follow-up visits compared to 
baseline. Blood pressure was significantly lower (p<0.05) at all follow-up visits compared 
to baseline in only the T2DM cohort of patients. 
Changes in serum levels of triglycerides decreased at each time point post-surgery 
and these changes were statistically significant (p<0.05) for both cohorts. For patients 
with prediabetes, triglycerides decreased from 1.9 ± 0.6 mmol/L to 1.4 ± 0.5 mmol/L 
(p<0.05) within 6 months and for patients with T2DM, triglyceride levels decreased from 
2.1 ± 0.8 mmol/L to 1.4 ± 0.5 mmol/L (p<0.05). Levels of HDL remained relatively 
constant in each cohort, with slight increases at 6 and 12 months, both of which were 
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statistically significant. Levels of low-density lipoprotein (LDL) were statistically 
significantly (p<0.05) lower at 3 months compared to baseline for the prediabetes cohort; 
however, for the T2DM cohort LDL at 12 months was statistically significantly (p<0.05) 
lower compared to baseline. For both cohorts, total cholesterol levels showed a 
statistically significant (p<0.05) decrease within 3 months following surgery. Fasting 
ratios (cholesterol/HDL) were lower at each time point post-surgery and these changes 
were statistically significant (p<0.05) compared to baseline for both cohorts.  
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Table 4.7 
 
Changes in weight, BMI, blood pressure, triglycerides, and fasting lipid panel in patients with prediabetes and T2DM 
 Prediabetes T2DM 
 Baseline 
(n=21) 
3 Months 
(n=18) 
6 Months 
(n=18) 
12 Months 
(n=17) 
Baseline 
(n=59) 
3 Months 
(n=53) 
6 Months 
(n=54) 
12 Months 
(n=24) 
Weight, kg 128.0 ± 22.3  106.8 ± 19.1* 98.7 ± 15.8* 92.1 ± 16.1* 139.3 ± 24.7 117.8 ± 21.4* 110.9 ± 21.1* 99.7 ± 13.5* 
Absolute Change 
in Weight, kg 
- 20.7 ±6.0 29.8 ± 9.2 40.2 ± 13.4 - 21.0 ± 5.9 29.1 ± 8.4 37.0 ± 12.8 
BMI, kg/m2 46.9 ± 6.8 39.5 ± 6.1* 36.2 ± 5.3* 33.4 ± 4.7* 49.6 ± 7.0 42.2 ± 6.2* 39.5 ± 6.0* 36.8 ± 4.0* 
%EWL - 32.1 ± 7.7 45.2 ± 9.4 58.1 ± 15.1 - 28.6 ± 7.4 39.1 ± 10.0 48.8 ± 10.1 
%AWL - 16.1 ± 3.3 22.9 ± 4.6 30.2 ± 7.8 - 15.1 ± 3.1 20.8 ± 4.6 26.6 ± 6.2 
         
Blood Pressure, 
mmHg 
        
Systolic 131 ± 12 126 ± 13 126 ± 15 129 ± 18 130 ± 14 121 ± 16* 119 ± 12* 123 ± 17* 
Diastolic 83 ± 10 81 ± 10 81 ± 9 80 ± 11 80 ± 10 74 ± 11* 74 ± 10* 75 ± 11* 
         
Fasting Lipid 
Panel, mmol/L 
(n=21) (n=15) (n=17) (n=10) (n=59) (n=50) (n=50) (n=24) 
Triglycerides 1.9 ± 0.6 1.4 ± 0.5* 1.4 ± 0.5* 1.3 ± 0.5* 2.1 ± 0.8 1.6 ± 0.5* 1.4 ± 0.5* 1.5 ± 0.5* 
HDL 1.1 ± 0.2 1.1 ± 0.1 1.2 ± 0.2* 1.5 ± 0.3* 1.0 ± 0.2 1.0 ± 0.2 1.1 ± 0.2* 1.3 ± 0.3* 
LDL 3.1 ± 1.1 2.6 ± 0.8* 2.7 ± 0.8 3.0 ± 1.1 2.6 ± 1.0 2.5 ± 1.0 2.6 ± 1.0 3.0 ± 0.8* 
Total Cholesterol 5.0 ± 1.3 4.4 ± 0.9* 4.6 ± 1.0 5.1 ± 1.1 4.5 ± 1.0 4.2 ± 1.1* 4.3 ± 1.0 4.9 ± 0.9 
Fasting Ratio 
(Cholesterol/HDL) 
4.8 ± 1.1 4.1 ± 1.0* 3.9 ± 0.9* 3.6 ± 1.1* 4.8 ± 1.3 4.3 ± 1.3* 4.1 ± 1.2* 4.0 ± 1.0* 
Note: %AWL=percent absolute weight loss, BMI=body mass index, %EWL=percent excess weight loss, HDL=high-density 
lipoprotein, LDL=low-density lipoprotein, T2DM=type 2 diabetes mellitus. Analysis was carried out using generalized 
estimating equations. 
*p<0.05 compared to baseline
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As previously discussed, serum levels of triglycerides can be indicative of insulin 
resistance; as T2DM improves and insulin resistance decreases, triglyceride levels should 
also improve. Figure 4.4 illustrates the changes in BMI and levels of A1c and 
triglycerides post-surgery. All three variables decreased almost in parallel post-surgery; 
however, the most dramatic decreases in BMI, A1c, and triglycerides occurred within the 
first three months following surgery. Average BMI and levels of A1c decreased at each 
visit post-surgery. There was a slight increase in triglyceride levels at 12 months post-
surgery compared to levels at 6 months but this could potentially be due to the low 
number of patients who had returned at 12 months. 
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Figure 4.4. T2DM cohort, changes in: a) BMI (kg/m2), b) A1c (%), and c) Triglycerides 
(mmol/L) post-surgery. A1c=glycated hemoglobin, BMI=body mass index. 
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In examining the changes in medication use post-surgery the focus was on the 
T2DM cohort of patients as only one patient in the prediabetes cohort was taking 
antidiabetic medications prior to surgery and this patient no longer required the use of 
medication post-surgery. The antidiabetic medications included in this analysis are 
biguanide (metformin), sulfonylureas (gliclazide, glyburide), alpha glucosidase inhibitor 
(acarbose), DPP-4-inhibitors (saxagliptin, sitagliptin), meglitinides (repaglinide, 
nateglinide), thiazolidinediones (pioglitazone, rosiglitazone), GLP-1 receptor agonists 
(liraglutide), rapid-acting insulin (insulin lispro, insulin aspart), fast-acting insulin 
(regular insulin), intermediate-acting insulin (insulin NPH), and long-acting insulin 
(insulin glargine, insulin detemir).   
At baseline, 42 patients (71.2% of the sample) with T2DM were taking 
antidiabetic medications. The 15 (25.4%) patients who were not taking antidiabetic 
medications at baseline were not prescribed medications for diabetes at any time post-
surgery; therefore, the analysis will focus on the 42 patients who were taking antidiabetic 
medications prior to LSG. The changes in medication use post-surgery are presented in 
Table 4.8. Within one month after surgery, only 20 of 41 (48.8%) patients who were 
taking antidiabetic medications before surgery were still taking medication. By the 6 
month follow-up, only 16 of 34 (47.1%) patients still required the use of antidiabetic 
medications. With respect to the number of medications patients required, at baseline the 
number of medications ranged from 1 to 4 with a mean value of 2.0 ± 1.0 medications but 
by 6 months post-surgery patients required only 1 or 2 medications with an average of 1.3 
± 0.4. All classes of antidiabetic medications show decreases in the proportion of people 
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taking medications at each visit post-surgery as well as decreases in the average dose of 
medication required. Of particular interest is the change in insulin use post-surgery. At 
baseline, 30 of 42 (71.4%) patients reported using insulin but at 6 months, only 6 of 34 
(17.6%) patients still required insulin for diabetes management. 
To aid the discussion of changes in HDL, LDL, triglycerides, and total 
cholesterol, Table 4.9 presents data on changes in the use of HMG CoA Reductase 
Inhibitors, or statins, post-surgery in the diabetic population. The statins of interest are 
rosuvastatin, atorvastatin, simvastatin, pravastatin, and lovastatin. At baseline, 31 patients 
(52.5% of the sample [n=59]) with T2DM were taking statins. By 6 months post-surgery, 
18 of  25 (72.0%) patients still required the use of statins. Of the five statins of interest, 
patients were only ever prescribed rosuvastatin, atorvastatin, or pravastatin. All three 
statins showed a decrease in use and dose post-surgery; however, by 6 months post-
surgery, patients no longer required the use of pravastatin. While the use of statins did 
decrease post-surgery the reduction was not as substantial as was seen in the use of 
antidiabetic medications post-surgery. 
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Table 4.8 
 
Changes in antidiabetic medication use before and after patients with T2DM underwent 
LSG  
 Baseline 
(n=42) 
1 Month 
(n=41) 
3 Months 
(n=36) 
6 Months 
(n=34) 
12 Months 
(n=20) 
Taking Antidiabetic 
Medications, n(%) 
42 (100.0) 20 (48.8) 16 (44.4) 16 (47.1) 5 (25.0) 
Average Number of 
Medications, mean ± SD 
[Min-Max] 
2.0 ± 1.0 
[1-4] 
1.7 ± 0.8 
[1-4] 
1.7 ± 0.9 
[1-4] 
1.3 ± 0.4 
[1-2] 
1.0 ± 0.0 
[1] 
Biguanide      
Metformin, n(%) 34 (81.0) 10 (24.4) 13 (36.1) 13 (38.2) 4 (20.0) 
Average Dose (mg) 1619 ± 556 
[500-2550] 
1472 ± 740 
[500-2550] 
1254 ± 615 
[250-2000] 
1163 ± 709 
[425-2500] 
1231 ± 888 
[425-2000] 
Sulfonylureas, n(%) 11 (26.2) 4 (9.8) 3 (8.3) 2 (5.9) 0 (0) 
Gliclazide, n(%) 7 (16.7) 3 (7.3) 2 (5.5) 1 (2.9) 0 (0) 
Average Dose (mg) 118.6  ± 71.3 
[30-240] 
85.0 ± 72.6 
[15-160] 
87.5 ± 102.5 
[15-160] 
30.0 ± 0.0 - 
Glyburide, n(%) 4 (9.5) 1 (2.4) 1 (2.8) 1 (2.9) 0 (0) 
Average Dose (mg) 12.5 ± 5.0 
[10-20] 
20.0 ± 0.0 
 
20.0 ± 0.0 10.0 ± 0.0  - 
Alpha-Glucosidase 
Inhibitor, n(%) 
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
DPP-4 Inhibitors, n(%) 3 (7.1) 1 (2.4) 1 (2.8) 1 (2.9) 0 (0) 
Saxagliptin, n(%) 1 (2.4) 0 (0) 0 (0) 0 (0) 0 (0) 
Average Dose (mg) 5.0 ± 0.0 - - - - 
Sitagliptin, n(%) 2 (4.8) 1 (2.4) 1 (2.8) 1 (2.9) 0 (0) 
Average Dose (mg) 100 ± 0.0 50 ± 0.0 50 ± 0.0 50 ± 0.0 - 
Meglitinides, n(%) 2 (4.8) 0 (0) 0 (0) 0 (0) 0 (0) 
Repaglinigde, n(%) 2 (4.8) 0 (0) 0 (0) 0 (0) 0 (0) 
Average Dose (mg) 2.5 ± 2.1 
[1-4] 
- - - - 
Nateglinide, n(%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Thiazolidinediones, n(%) 1 (2.4) 1 (2.4) 0 (0) 0 (0) 0 (0) 
Pioglitazone, n(%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Rosiglitazone, n(%) 1 (2.4) 1 (2.4) 0 (0) 0 (0) 0 (0) 
Average Dose (mg) 4.0 ± 0.0 4.0 ± 0.0 - - - 
GLP-1 Receptor Agonist, 
n(%) 
4 (9.5) 1 (2.4) 0 (0) 0 (0) 0 (0) 
Liraglutide, n(%) 4 (9.5) 1 (2.4) 0 (0) 0 (0) 0 (0) 
Average Dose (mg) 1.5 ± 0.3 
[1.2-1.8] 
1.2 ± 0.0 - - - 
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Insulin, n(%) 30 (71.4) 17 (41.5) 10 (27.8) 6 (17.6) 1 (5.0) 
Rapid-acting, n(%) 9 (21.4) 5 (12.2) 3 (8.3) 2 (5.9) 0 (0) 
Insulin lispro, n(%) 5 (11.9) 4 (9.8) 2 (5.6) 1 (2.9) 0 (0) 
Average Dose, (U) 75.0 ± 48.5 
[36-135] 
27.0 ± 4.2 
[24-30] 
30.0 ± 0.0 n/a -  
Insulin aspart, n(%) 4 (9.5) 1 (2.4) 1 (2.8) 1 (2.9) 0 (0) 
Average Dose (U) 110.0 ± 45.8 
[60-150] 
n/a n/a n/a - 
Fast-acting, n(%)      
Regular insulin, n(%) 5 (11.9) 2 (4.8) 1 (2.8) 1 (2.9) 0 (0) 
Average Dose, (U) 68.0 ± 40.0 
[21-105] 
38.0 ± 31.0 
[16-60] 
15.0 ± 0.0 n/a - 
Intermediate-acting, 
n(%) 
     
Insulin NPH, n(%) 6 (14.3) 3 (7.3) 1 (2.8) 0 (0) 0 (0) 
Average Dose, (U) 66.0 ± 28.0 
[42-100] 
52.0 ± 14.0 
[36-60] 
60.0 ± 0.0 
 
- - 
Long-acting, n(%) 10 (23.8) 7 (17.1) 5 (13.9) 3 (8.8) 1 (5.0) 
Insulin glargine, n(%) 5 (11.9) 4 (9.8) 2 (5.6) 2 (5.9) 0 (0) 
Average Dose, (U) 88.6 ± 55.1 
[28-175] 
49.8 ± 22.4 
[24-75] 
42.0 ± 25.5 
[24-60] 
43.0 ± 38.2 
[16-70] 
- 
Insulin detemir, n(%) 5 (11.9) 3 (7.3) 3 (8.3) 1 (2.9) 1 (5.0) 
Average Dose, (U) 121.4 ± 29.4 
[90-165] 
53.3 ± 40.4 
[10-90] 
53.3 ± 40.4 
[10-90] 
25.0 ± 0.0 50.0 ± 0.0 
Note: LSG=laparoscopic sleeve gastrectomy, max=maximum, mg=miligrams, 
min=minimum, n/a=not available, SD=standard deviation, T2DM=type 2 diabetes 
mellitus, U=units. Average doses reported as mean ± SD and [minimum dose-maximum 
dose]. 
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Table 4.9 
 
Changes in statin use before and after patients with T2DM underwent LSG  
 Baseline 
(n=31) 
1 Month 
(n=31) 
3 Months 
(n=28) 
6 Months 
(n=25) 
12 Months 
(n=13) 
Taking Statins, n(%) 31 (100.0) 27 (87.1) 23 (82.1) 18 (72.0) 8 (61.5) 
Rosuvastatin, n(%) 21 (67.7) 19 (70.4) 15 (65.2) 14 (77.8) 5 (62.5) 
Average Dose (mg) 13.3 ± 5.8 
[5-20] 
13.0 ± 6.2 
[5-20] 
12.3 ± 6.2 
[5-20] 
11.4 ± 6.0 
[5-20] 
13.0 ± 6.7 
[5-20] 
Atorvastatin, n(%) 9 (29.0) 7 (25.9) 7 (30.4) 4 (12.9) 3 (37.5) 
Average Dose (mg) 22.5  ± 18.3 
[10-60] 
21.4 ± 20.4 
[10-60] 
22.9 ± 19.8 
[10-60] 
20.0 ± 14.1 
[10-40] 
13.3 ± 5.8 
[10-20] 
Simvastatin, n(%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Average Dose (mg) - - - - - 
Pravastatin, n(%) 1 (3.2) 1 (3.7) 1 (4.3) 0 (0) 0 (0) 
Average Dose (mg) 20 ± 0.0 20 ± 0.0 20 ± 0.0 - - 
Lovastatin, n(%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Average Dose (mg) - - - - - 
Note: Average doses reported as mean ± SD and [minimum dose-maximum dose]. 
LSG=laparoscopic sleeve gastrectomy, mg=miligrams, SD=standard deviation, 
T2DM=type 2 diabetes mellitus. 
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Chapter 5: Discussion 
 
 The current study examined the improvement and remission of prediabetes and 
T2DM following LSG in patients living in NL by reporting the proportion of patients 
experiencing either improvement or remission at 12 months post-surgery. This study also 
examined changes in glycemic measures (A1c and FPG), antidiabetic medication use, 
weight, blood pressure, triglycerides, and fasting lipid panel and explored potential 
factors associated with remission of prediabetes and T2DM. 
 The discussion of the results is organized based on the research questions outlined 
in Chapter 1. The first section describes how this sample of patients compares to other 
samples with respect to baseline demographics and obesity-related comorbidities. The 
second section discusses the proportion of patients who achieve improvement or 
remission of prediabetes as well as changes in glycemic measures for this group. The 
third section discusses similar outcomes for the T2DM cohort. The fourth section 
discusses baseline factors that may be associated with the likelihood of a patient 
achieving remission of prediabetes or T2DM post-surgery. The fifth section assesses the 
secondary outcomes – changes in weight, blood pressure, triglycerides, fasting lipid 
panel, and antidiabetic medication use. 
5.1 Baseline Demographics, Comorbidity Profile, & Laboratory Values 
 
 The demographics and initial levels of FPG and A1c of patients with T2DM 
undergoing LSG in NL were comparable to other populations that have been studied. The 
current study reported on a predominantly female diabetic population (76.1%) with an 
97 
 
average age of 45.0 ± 10.4 years and an initial average BMI of 49.3 ± 7.0 kg/m2. Average 
pre-operative FPG levels were 8.5 ± 2.9 mmol/L and average levels of A1c were 7.8 ± 
1.4% initially. A systematic review by Gill et al. (2010) included 673 patients in 27 
studies and reported an average age of 46.6 years that was, on average, 66% female with 
an average initial BMI of 47.4 kg/m2. Initial levels of FPG were, on average, 10.1 
mmol/L and average initial A1c values were 7.9% (Gill et al., 2010). While the average 
FPG levels in the systematic review were slightly elevated when compared to this study, 
the populations appear to be similar in all other aspects related to baseline characteristics. 
 A study by Padwal et al. (2012) described the characteristics of the population 
receiving publicly funded bariatric surgery in Canada. The sample (n=91) in the current 
study showed similarities to the Canadian population undergoing bariatric surgery with 
respect to average age, ethnicity, proportion of females, and level of education. For 
example, in Canada, the average age of surgical patients is 43.6 ± 11.1 years, 87.1% are 
Caucasian, and 82% of the population is female. In the current study, the average age was 
45.6 ± 10.4 years, 90.1% of the sample was Caucasian, and 76.9% of the sample was 
female. The authors described patients undergoing surgery as highly educated, with 
56.9% of the eligible population having received some post-secondary education, similar 
to that of the current study sample (63.9% of the sample had received a college diploma 
or university degree). However, the prevalence of obesity-related comorbidities was much 
higher in the NL sample compared to the Canadian population undergoing bariatric 
surgery. Of the Canadian population receiving surgery, 13.1% reported a history of 
hypertension compared to 67.8% of the current sample, 21.1% report a history of diabetes 
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compared to 62.8%, 10.9% report a history of sleep apnea compared to 61.6%, and only 
2.4% report a history of dyslipidemia compared to 60.5% of the current sample. This 
could be a consequence of candidate pre-selection in other health care jurisdictions in 
Canada, whereby healthier patients are selected to undergo bariatric surgery in an effort to 
not impact surgical risk or length of stay. 
5.2 Prediabetes 
 
There is very little published data on the effects of LSG on patients with obesity 
and prediabetes. Only one published study was identified on this topic; however, the 
definitions of improvement and remission were different from those used in the current 
study as was the diagnostic technique used for identifying patients with prediabetes 
(Natoudi et al., 2014). 
5.2.1 Proportion of Patients Achieving Improvement or Remission of 
Prediabetes. In the current study sample, 11 patients (52.4%) had complete 12 month 
data and were therefore included in this analysis. The study by Natoudi et al. (2014) 
reported outcomes for 20 patients with prediabetes; however, the sample was only 25% 
female compared to the 79.2% female sample of prediabetic patients in the current study. 
Within 12 months post-surgery, Natoudi et al. (2014) reported that all 20 patients 
who were initially classified as prediabetic were reclassified as having normal glycemic 
measures. The current study reported that 9 patients, or 81.8% of the sample with 
prediabetes that had complete 12 month data, had achieved remission of prediabetes and 
the remaining 2 patients had normal glycemic measures for a period of 6 months. The 
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results from this analysis are similar to those obtained by Natoudi and colleagues (2014) 
however, more follow-up is needed on this specific patient population before any 
conclusions can be drawn on the effect of LSG on prediabetes. 
5.2.2 Changes in Glycemic Measures. The current study suggests that patients 
with prediabetes achieved significant changes in FPG and A1c levels within 12 months 
post-surgery. The study by Natoudi et al. (2014) reported only on changes in oral glucose 
tolerance test results thus direct changes in glycemic measures cannot be compared. The 
largest change in glycemic measures in the current study happened within the first 3 
months following surgery with FPG decreasing from 5.8 mmol/L to 5.1 mmol/L (p<0.01) 
and A1c levels decreasing from 5.9% to 5.5% (p<0.01). Normal levels for FPG and A1c 
are considered to be 6.0 mmol/L and 6.0%, respectively and by 3 months post-surgery the 
patients within one standard deviation of the average value had achieved normal levels of 
FPG and A1c. At both 6 and 12 months following surgery FPG and A1c levels remained 
consistent with the 3 month results, although the findings should be interpreted with 
caution as only 11 patients (52.4%) had returned for the 12 month visit at the time of this 
analysis. The mechanism behind the immediate decline in levels of FPG and A1c within 
the first 3 months following LSG in this study is not certain. It may be attributed to 
weight loss but it is more likely attributed to either changes in the secretion of gut 
hormones or reduced caloric intake post-surgery. These mechanisms will be discussed 
further in section 5.3.2. 
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5.3 T2DM 
 
 5.3.1 Proportion of Patients Achieving Improvement or Remission of T2DM.  
24 T2DM patients (40.7%) had complete 12 month data and were therefore included in 
this analysis. This sample size is similar to that of other studies looking at the 
effectiveness of LSG on the improvement or remission of T2DM in a 12 month period as 
outlined in the literature review which had a median sample size of 22 patients (range: 6-
75) (Desiderio et al., 2013a, Gill et al., 2010, Slater et al., 2011).  
 Of the 11 studies in the literature review that reported results on improvement of 
T2DM after a period of 12 months, a range of 2%-86% of patients achieved improvement 
with a median value of 24% (Desiderio et al., 2013a, Gill et al., 2010, Slater et al., 2011). 
The proportion of patients that experienced improvement of T2DM in the current study 
was 20.8% which is on the lower end of the spectrum compared to other published 
studies. A total of 14 studies reported on remission of T2DM 12 months post-surgery 
with a range of 14%-98% achieving remission (median 71%) compared to 25% of the 
current sample achieving remission within 12 months (Desiderio et al., 2013a, Gill et al., 
2010, Slater et al., 2011). While the proportions of patients achieving improvement and 
remission in the current study are lower than those reported in the literature, not all 
studies are using the same definition of improvement and remission as no standard 
definition has been accepted; thus, it is hard to make comparisons between studies. 
Two recent studies with a follow-up period of 12 months have used the same 
criteria for improvement and remission as the current study. A study conducted by Slater 
et al. (2011) comprised of 22 patients reported 75% of patients achieved remission and 
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25% experienced improvement of T2DM. A second study by Desiderio et al. (2013a) 
reported on the 12 month outcomes of 15 patients noting 40% of patients achieved 
complete remission and 33.3% achieved partial remission of T2DM while the remaining 
26.7% were stable in their disease status. When comparing the current results to studies 
with similar definitions of improvement and remission, the current data suggests lower 
rates of remission and improvement within the first 12 months following surgery. The 
reason for these discrepancies is not clear, but it may lie in the pre-operative differences 
between the two samples. The sample of patients in the study by Slater et al. (2011) was 
predominantly male (79% versus 23.9%) and was older (55.3 years versus 45 years); 
however, Slater and colleagues described a sample in which 55% of patients were using 
injectable insulin whereas 71.4% of patients in the current study were using injectable 
insulin at baseline. This could indicate that patients in the current study had more 
advanced diabetes and would therefore be less likely to experience remission of T2DM 
within the first 12 months following surgery. The study by Desiderio et al. (2013a) also 
described an older population (58.8 years versus 45 years) but with a lower average pre-
operative BMI than that of the current study (37.9 ± 1.5 kg/m2 versus 49.3 ± 7.0 kg/m2). 
The discrepancy in BMI could be the reason why Desiderio and colleagues reported a 
higher rate of remission than the current study as obesity is a major risk factor for the 
development of T2DM and patients that are more obese may have more severe diabetes 
or may have been diabetic for a longer period of time, making it less likely for them to 
achieve remission within just 12 months following surgery. 
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In contrast, a study by Pournaras et al. (2012) applied the definition of remission 
recommended by Buse and colleagues (2009) in a retrospective study of diabetic patients 
undergoing bariatric surgery and reported a remission rate of T2DM of 26% following 
LSG. The remission rate when the new definition of remission was applied was 
substantially lower than rates reported in previous studies but was more similar to the 
25% rate of remission in the current study. The two samples were similar in most pre-
operative characteristics. The sample in the study by Pournaras and colleagues was older 
(53 years versus 45 years) but had a similar initial average BMI (50 ± 8.0 kg/m2 versus 
49.3 ± 7.0 kg/m2), FPG (8.9 ± 4.2 mmol/L versus 8.5 ± 2.9 mmol/L), and A1c (7.5 ± 
1.5% versus 7.8 ± 1.4%); however, only 32% of patients in the study by Pournaras and 
colleagues were using insulin before surgery compared to 71.4% of patients in the current 
study. Thus, it is hard to conclude exactly why the proportions of patients experiencing 
remission of T2DM in these studies were so similar. 
 In summary, within the first 12 months post-surgery, improvement or remission of 
T2DM was seen in 20.8% and 25% of the sample, respectively; however, in this current 
study, a number of patients had yet to reach their 12-month post-operative appointment, 
which could affect the estimated percentages of improvement and remission. Due to the 
stringent case definitions of improvement and remission recommended by Buse et al. 
(2009), rates of remission of T2DM may be lower in studies using these criteria 
(Pournaras et al., 2012).  
5.3.2 Changes in Glycemic Measures. The current study indicated that patients 
experienced significant changes in FPG and A1c levels within 12 months post-surgery. 
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However, considering that only 40.7% of patients had returned at 12 months at the time 
of analysis, the focus will be on the 6 month results, for which 83.1% of patients had data. 
Within the first 6 months of having surgery FPG levels decreased on average by 2.6 
mmol/L and A1c levels decreased by an average of 1.7%.  
Two studies included in the systematic review conducted by Gill et al. (2010) 
published results on patients just 6 months after surgery and found levels of FPG to 
decrease by 2.0 mmol/L and 1.7 mmol/L and levels of A1c decreased by 1.6% and 0.5% 
(Gill et al., 2010). An additional study, which reported only on changes in A1c, observed 
a decrease of 1.3% within 6 months following surgery (Gill et al., 2010). Compared to 
these results, the sample in this study exhibited larger changes in both FPG and A1c 
within just 6 months post-surgery. Interestingly, the largest change in the current study 
occurred just 3 months after surgery; FPG levels decreased by 2.2 mmol/L to a level of 
6.4 ± 1.8 mmol/L and A1c levels decreased by 1.6% to a level of 6.3 ± 0.8% resulting in 
both average FPG and A1c levels below the diagnostic thresholds identified in the case 
definition of T2DM. Other published studies have similar findings, with levels of FPG 
and A1c dropping rapidly in the initial period following surgery (i.e., within the first 3 
months) with the rate of change slowing down by 6 months post-surgery (Desiderio et al., 
2013a). The study by Desiderio et al. (2013a) reported a pre-surgery FPG level of 9.9 ± 
1.7 mmol/L which decreased to 6.3 ± 1.0 mmol/L in just 60 days and remained at this 
level at both 6 and 12 months post-surgery. Similarly, pre-operative A1c levels were 8.1 
± 0.6 % and these levels dropped down to 6.1 ± 0.6% within the first 60 days following 
surgery and at 6 months decreased slightly to 5.9 ± 0.6% (Desiderio et al., 2013a). 
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The reasons for such a rapid change in glycemic measures in the current study and 
other published literature almost immediately after surgery are still under debate. The 
glucose-lowering effects of certain bariatric surgical procedures within just days after 
surgery, before significant weight-loss has occurred, have been known for decades; thus, 
the predominant hypotheses for these metabolic advantages after bariatric surgery include 
changed release of GI hormones and surgically induced restriction of food intake (Knop 
& Taylor, 2013). The change in the delivery of nutrients to the small intestine (i.e., food 
being delivered to the small intestine faster or to a more distal region of the small 
intestine) increases the GLP-1 response to a meal thus enhancing the insulin response and 
lowering blood glucose levels (Knop & Taylor, 2013). It remains to be seen what 
proportion of the enhanced postprandial insulin secretion is dependent on changes in 
incretin secretion and also what change in long-term β-cell function results from 
surgically induced increases in GLP-1 secretion (Knop & Taylor, 2013). With respect to 
surgically induced restriction of food intake, sudden negative calorie balance induced by 
any means in diabetic patients will normalize plasma glucose levels within days and this 
is believed to be the predominant mechanism underlying the early metabolic changes 
after bariatric surgery (Knop & Taylor, 2013).  
In summary, significant changes in glycemic measures occurred as early as 3 
months post-surgery. Average decreases in FPG and A1c observed in the current study 
within 6 months post-surgery were greater than what has been reported in similar studies. 
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5.4 Factors Associated with Remission of Prediabetes and T2DM  
 
The current study was unable to identify any baseline factors associated with the 
remission of T2DM following LSG. In contrast, one factor, baseline weight, was 
associated with remission of prediabetes 12 months post-surgery. This finding could be 
attributed to the fact that obesity is associated with insulin resistance; patients with lower 
weights and thus, less insulin resistance, may not have developed as severely elevated 
glucose levels prior to surgery making it more likely for them to experience remission due 
to the metabolic changes following LSG. The small sample size in this analysis could 
explain why more associations, particularly in the T2DM cohort, were not found. 
Furthermore, a variable indicative of remission of T2DM (duration of T2DM prior to 
surgery) was not available in the current study.  
Key pre-operative factors identified in the research literature as being predictive 
of remission of T2DM following bariatric surgery include: duration of T2DM, baseline 
BMI, baseline FPG and A1c levels, insulin use, waist circumference, and C-peptide levels 
(Casella et al., 2011; Lee et al., 2012; Robert et al., 2013). These studies have larger 
sample sizes (e.g., at least double the number of participants of the current study) and 
remission rates greater than 50%, thus making them better able to determine pre-operative 
indicators of remission.  
Furthermore, weight loss 12 months post-surgery was not associated with any 
changes in secondary outcomes following surgery for the prediabetic cohort; however, in 
the T2DM cohort, weight loss was associated with decreases in FPG (p<0.01) and 
increases in HDL (p=0.01) 12 months post-surgery. While weight loss alone cannot 
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entirely explain the improvement of T2DM post-surgery, the underlying factors 
contributing to weight loss may play a role in amelioration of FPG and HDL post-
surgery. One of the factors shown to contribute to weight loss is an increase in GLP-1 
production post-surgery which inhibits the release of glucagon and acts on the pancreas to 
secrete insulin (Miras & le Roux, 2013), both of which would ultimately lower levels of 
FPG. This increase in GLP-1 has also been hypothesized as a factor that may help explain 
the increase in HDL post-surgery (Zhang et al., 2011). 
5.5 Secondary Outcomes: Changes in Weight, Blood Pressure, Triglycerides, 
Cholesterol, and Antidiabetic Medication Use 
 
 Both the prediabetes and T2DM cohorts in the current study experienced 
significant changes in weight loss measures following LSG. A Canadian study by 
Behrens et al. (2011) that followed patients for an average of 10 months (range: 2-23 
months) reported that patients had an average weight loss of 27.4 kg with an average 
decrease in BMI of 10.4 kg/m2. These figures are comparable to those in the current study 
which reported an average weight loss of 29.3 kg and 28.4 kg for the prediabetes and 
T2DM cohorts, respectively, followed by an average decrease in BMI of 10.7 kg/m2 for 
the prediabetes cohort and 10.1 kg/m2 for the T2DM cohort within 6 months following 
surgery. Within 6 to 36 months following LSG, %EWL is expected to range from 45% to 
60% (Victorzon, 2012), comparable to the results seen in the current study with patients 
with prediabetes having lost 45.2 ± 9.4% of their excess weight and patients with T2DM 
having lost 39.1 ± 10.0% of their excess weight 6 months post-surgery. 
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 Bariatric surgical procedures were designed to restrict food intake and cause 
nutrient malabsorption; however, evidence suggests that these factors make minimal 
contributions to weight loss (Miras & le Roux, 2013). Instead, weight loss induced by 
bariatric surgery is a result of decreased hunger, increased satiation during a meal, 
changing food preferences, and energy expenditure (Miras & le Roux, 2013). Following 
LSG, postprandial levels of PYY and GLP-1 are markedly higher than before surgery 
(Miras & le Roux, 2013). PYY and GLP-1 are released in response to a meal and act on 
the hypothalamus to decrease food intake; however, it is still uncertain if GLP-1 is 
necessary for LSG-induced weight loss (Miras & le Roux, 2013). In contrast, levels of 
ghrelin, a hunger-inducing hormone that increases food intake, are reduced following 
LSG (Miras & le Roux, 2013). Changes in these three hormones following LSG act to 
decrease hunger and increase satiation during a meal ultimately resulting in restricted 
food intake by patients (Miras & le Roux, 2013).  
Bariatric surgical procedures also have an effect on the types of macronutrients 
chosen by patients, though most of the research has been conducted in patients that have 
undergone RYGB (Miras & le Roux, 2013). Regardless of dietary advice received by 
patients pre- or post-surgery, following RYGB, patients prefer to eat food low in fat 
and/or sugar suggesting that food preferences are predominantly affected by physiological 
processes as opposed to dietary recommendations and social acceptability bias (Miras & 
le Roux, 2013). While some animal studies have shown that LSG is associated with 
similar changes in food preference as is seen following RYGB, more research is needed 
to truly understand changing food preferences following LSG (Miras & le Roux, 2013).  
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In looking at changes in energy expenditure following LSG, rodent models have 
demonstrated either stability or a decrease in resting energy expenditure post-surgery 
(Miras & le Roux, 2013). However, human and animal studies have demonstrated an 
increase in diet-induced energy expenditure following RYGB but the underlying 
mechanisms are still unknown (Miras & le Roux, 2013). More research is needed to 
assess the effects of LSG on diet-induced energy expenditure. 
 Changes in blood pressure post-surgery for the prediabetes cohort were not 
significant when compared to baseline but did decrease from an average of 131/83 ± 
12/10 mmHg to 126/81 ± 15/9 mmHg within 6 months post-surgery. By 12 months post-
surgery with 17 patients (81.0%) having returned for follow-up the average blood 
pressure was 129/80 ± 18/11 mmHg. Changes in blood pressure for patients with T2DM 
did prove to be statistically significant at each follow-up appointment post-surgery 
compared to baseline. Initially in this cohort the average blood pressure was 130/80 ± 
14/10 mmHg which decreased to an average of 119/74 ± 12/10 mmHg within the first 6 
months following surgery (p<0.05). Existing literature has also reported similar 
improvements in blood pressure in diabetic populations following LSG. A study by Lee et 
al. (2011) which did not report on baseline values reported a decrease in both systolic and 
diastolic blood pressure at 12 months post-surgery to an average level of 124/75 ± 10/9 
mmHg which is a similar value to the 12 month blood pressure reported in this study 
(123/75 ± 17/11) with only 42.4% of the sample having returned at the time of analysis. A 
study by Desiderio et al. (2013b) investigating the effects of LSG in patients with severe 
obesity and metabolic disorders also reported significant changes in blood pressure post-
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surgery. The baseline average blood pressure was reported as 136/87 ± 19/8 mmHg and 
decreased to 120/80 ± 13/5 mmHg and 117/78 ± 9/4 mmHg at 6 and 12 months post-
surgery, respectively (Desiderio et al., 2013b). 
Levels of serum triglycerides decreased significantly in both cohorts in the current 
study, which is a secondary indicator of improvement in insulin resistance and thus an 
indicator of improvement of diabetes as well. Initially both cohorts had average 
triglyceride levels outside the reference range (0.0-1.7 mmol/L). Initial triglyceride levels 
were 1.9 ± 0.6 mmol/ L and 2.1 ± 0.8 for the prediabetes and T2DM cohorts, respectively. 
6 months post-surgery these average levels fell to within the reference range; average 
triglycerides levels were 1.4 ± 0.5 mmol/L for both cohorts (p<0.05). This trend has also 
been seen in similar studies which have reported triglyceride levels initially higher than 
the reference range dropping after surgery to levels within the normal reference range 
(Chowbey et al., 2010; Perathoner et al., 2013).  
With respect to serum cholesterol levels, levels of HDL slowly increased post-
surgery with both cohorts exhibiting an increase beginning at the 6-month follow-up 
appointment, which was statistically significant. Both cohorts showed an average increase 
of 0.1 mmol/L in HDL at 6 months and the 12 month data thus far showed a further 
increase; however, 12 month results should be interpreted with caution as not all patients 
had returned for 12 month follow-up at the time of this analysis. This is consistent with 
the results in a study by Perathoner et al. (2013), which showed an increase in HDL levels 
of 0.2 mmol/L after an average follow-up time of 17.4 months. As noted in Chapter 4, 
pre-surgery levels of LDL and total cholesterol were lower in the T2DM cohort than in 
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the prediabetes cohort. While this is counterintuitive as dyslipidemia is a comorbidity 
associated with both obesity and T2DM it is likely due to the fact that more diabetic 
patients were taking statins at baseline (52.5%) than were prediabetic patients (28.6%). A 
closer examination of levels of LDL and total cholesterol, indicated that both appeared to 
be decreasing at 3 months following surgery but at both 6 and 12 months follow-up the 
levels were once again rising and even surpassed the pre-operative means but was only 
statistically significant for the T2DM cohort. Perathoner and colleagues (2013) reported 
similar results with respect to total cholesterol with baseline and post-operative levels 
being equal; however, the authors reported an overall decrease in levels of LDL, although 
the finding was not statistically significant. Furthermore, the use of statins, which act to 
decrease levels of triglycerides, LDL, and total cholesterol and increase levels of HDL, 
decreased slightly following surgery thus medication use was not likely responsible for 
the changes in lipid profiles post-surgery. 
Bariatric surgical procedures can improve dyslipidemia associated with obesity; 
however, the impact varies based on surgical procedure (Zhang et al., 2011). 
Malabsorptive procedures have been shown to improve all of the variables in the lipid 
profile while restrictive procedures like LSG primarily increase HDL, reduce 
triglycerides, and show modest improvements in total cholesterol (Zhang et al., 2011). 
The exact mechanism behind these changes in lipid profiles is not clear but increases in 
ghrelin and GLP-1 production may help explain the effect of LSG on HDL and 
triglycerides (Zhang et al., 2011). It has also been speculated that the decreased 
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availability of free fatty acids and the negative energy balance produced by surgery may 
also contribute to changes in lipid profiles following LSG (Zhang et al., 2011). 
Changes in the use of antidiabetic medications post-surgery were analyzed only 
for patients with T2DM as only one patient with prediabetes was prescribed an 
antidiabetic agent prior to surgery. The proportion of patients taking antidiabetic agents 
decreased to 47.1% within 6 months of undergoing LSG. At the 12 month follow-up 
appointment the number of patients taking antidiabetic medications had decreased to 25% 
but this should be interpreted with caution as only 20 of 42 (47.6%) patients had returned 
at the time of analysis. As the proportion of patients taking medications post-surgery 
decreased, so did the average number of medications that patients required. On average, 
patients were taking 2.0 ± 1.0 (range: 1-4) medications before surgery and this number 
decreased to 1.3 ± 0.4 (range: 1-2) at 6 months post-surgery. Within this initial 6 month 
period after surgery patients who still required the use of antidiabetic agents only required 
approximately half of the amount of medications they had been initially prescribed. It 
follows that the proportion of patients taking the major classes of antidiabetic medications 
also decreased post-surgery. Prior to surgery 81% of patients were taking biguanides, 
26.2% were taking sulfonylureas, 7.1% were taking DPP-4 inhibitors, 4.8% were taking 
meglitinides, 2.4% were taking thiazolidinediones, 9.5% were taking a GLP-1 receptor 
agonist, and 71.4% were taking insulin with these proportions decreasing to 38.2%, 5.9%, 
2.9%, 0%, 0%, 0%, and 17.6%, respectively, 6 months post-surgery. Within 6 months 
post-surgery patients no longer required the use of drugs from the classes of meglitinides, 
thiazolidinediones, and GLP-1 receptor agonists. 
112 
 
 The results presented in this study are similar to results from other comparable 
studies. A study by Schauer et al. (2012) showed similar reductions in the proportions of 
patients requiring the use of biguanides and insulin following LSG. The proportion of 
patients taking biguanides decreased from 84% to 39% and the proportion of patients 
taking insulin decreased from 45% to 8% within 12 months post-surgery. Also, similar to 
the current study, patients were taking a maximum of only 2 antidiabetic agents 12 
months following surgery. Another study examining the proportion of patients requiring 
antidiabetic medications after undergoing LSG found that within 12 months following 
surgery only 17.7% of patients required the use of antidiabetic agents post-surgery (Ruiz 
de Gorejuela et al., 2011). Finally, Rosenthal et al. (2009) reported that following LSG 
oral hypoglycemic agent use decreased from 73% to 30% and insulin use decreased from 
27% to 7% 6 months after surgery. 
 Antidiabetic medications help control blood glucose levels but they often are 
unable to prevent the progression of diabetes which leads to other macrovascular 
complications. As patients experience metabolic improvements following LSG and go on 
to experience either remission or improvement of prediabetes or T2DM their bodies 
become better able to control blood glucose levels on their own; thus, patients require 
fewer medications and lower doses of medications, if they require the use of medication 
at all. The results of the current study indicate that patients require significantly fewer 
medications within 6 months post-surgery and these results are consistent with what other 
studies are reporting at 6 months post-surgery in obese, diabetic populations undergoing 
LSG. 
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In summary, both the prediabetes and T2DM cohorts achieved weight loss 
following LSG that was both statistically and clinically significant and as patients 
experienced improvement or remission of prediabetes or T2DM, triglyceride levels also 
improved further indicating an improvement in insulin resistance in the sample. Changes 
in fasting lipid panels were variable, while levels of HDL slowly increased after surgery, 
levels of LDL and total cholesterol initially decreased but then began to return to, or 
exceed, pre-operative levels. While all patients experienced lower blood pressure levels 
post-surgery, only patients in the T2DM cohort experienced changes that were 
statistically significant. Patients also required fewer antidiabetic medications post-
surgery, and a decrease was also seen in the dose of required medications within 12 
months post-surgery. 
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Chapter 6: Strengths and Limitations, Clinical Implications and Knowledge 
Translation, Future Research, and Conclusions 
 
 This chapter will summarize the strengths and limitations, clinical implications 
and knowledge translation, future research, and conclusions of this study. The first 
section includes a description and discussion of the strengths and limitations of this study. 
The second section outlines the clinical implications of this research and the importance 
of integrated knowledge translation. The third section describes proposals for future 
research on this topic and the final section summarizes the conclusions of this study. 
6.1 Strengths and Limitations 
 This study had both strengths and limitations a number of which are inherent in its 
design. The current study was strengthened by multiple factors. This study was a part of 
the ongoing NL BaSco Study enabling this research to include all patients who had 
undergone LSG and had consented to take part in research from the time bariatric surgery 
began being offered in NL in May 2011. Creating a case definition for prediabetes and 
T2DM eliminated the necessity of relying on self-reported medical history to identify 
patients with hypergylcemia thus ensuring that the study captured all eligible patients. 
Also, this research was one of the first studies in a Canadian health care setting to take 
into consideration what happens to patients with prediabetes following LSG. Other 
research suggests that by studying this patient population there is a chance to reduce the 
incidence of T2DM in obese populations through bariatric surgery (Natoudi et al., 2013). 
 This study had a number of limitations. Selection, sampling, and referral bias are 
all inherent in inception cohort studies. Selection bias in this study exists in the fact that 
115 
 
patients are seeking bariatric surgery on their own, through their family physician, 
making the sample of patients not truly random. The sample population seeking bariatric 
surgery may be more motivated to lose weight and make the necessary lifestyle changes 
to improve their health; thus, the outcomes seen in this sample may be overestimated 
compared to the general population which leads to the second type of bias, sampling bias.  
Sampling bias is error that arises due to the sample selection. Once patients have 
consented to be part of the study and provide data on their health outcomes to the research 
team the actual collection of data is dependent on patients returning for follow-up 
appointments. When patients do not return for appointments, no data is collected and the 
research team cannot make any conclusions about their health outcomes post-surgery. 
The group of patients that do return post-surgery are adhering to follow-up and are most 
likely to be patients having a positive post-surgery experience thus potentially skewing 
the results in a more positive way.  
Referral bias occurred in the method used to identify patients with either 
prediabetes or T2DM pre-operatively. While creating a case definition for prediabetes and 
T2DM was helpful in capturing patients who did not self-report a medical history of 
diabetes, it cannot be considered as a diagnosis of either condition as the gold standard 
test was not used. The gold standard for diagnosing diabetes would involve an OGTT 
which is not required before undergoing bariatric surgery; thus, a case definition using 
FPG and A1c levels was created based on recommendations by the CDA.  
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However, the results of the study are generalizable to other bariatric surgery 
populations with compliant patients. The average age of the current sample was 45.6 ± 
10.4 years, 90.1% were Caucasian, 76.9% of the sample was female, and average pre-
surgery BMI was 48.6 ± 7.1 kg/m2. The cohort characteristics were similar to bariatric 
surgical patients across the country (Padwal et al., 2012), increasing the generalizability 
of the study results to other Canadian jurisdictions as well as other publicly funded health 
care systems. 
As previously mentioned, baseline levels of FPG, triglycerides, LDL, and total 
cholesterol and baseline weight and blood pressure were recorded after patients had 
completed a one week full fluid diet, possibly resulting in an underestimation of these 
baseline values as they would be lower following the diet. Of all of the baseline levels 
mentioned above, FPG could most certainly be significantly reduced within one week of a 
full fluid diet; it is likely to be the one factor most affected within this time frame. The 
results of the current study should be interpreted with caution because, if these values had 
been recorded prior to the full fluid diet, then the magnitude of changes in blood glucose 
levels, weight, blood pressure, etc. would be even greater than what was reported. 
Furthermore, the prevalence of blood glucose levels diagnostic of prediabetes and T2DM 
could also be higher prior to the full fluid diet than after its initiation; thus, leading to an 
underestimation of the prevalence of these conditions in the current cohort of patients. 
This may also lead to information bias. 
Information bias, specifically misclassification bias, is another type of bias that 
may be present in this study. This type of bias may have occurred as there is a chance that 
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diseased patients (i.e., patients with prediabetes or T2DM) may have been classified as 
non-diseased and vice versa for the reason stated above or also because the identification 
of disease state was not carried out by a medical professional who was familiar with each 
patient’s medical history. 
Finally, this study reports short-term results within 12 months following surgery 
and is an analysis of a subsample of the population of the NL BaSco Study. For a patient 
to be considered as having improved prediabetes or T2DM or in remission of either 
disease the criteria must have been met for a period of 12 months; thus, this study is only 
capturing patients who experience improvements immediately following surgery (i.e., 
normal glycemic measures 3 months post-surgery). This may have caused the estimate of 
the proportion of patients experiencing remission post-surgery to be lower than what is 
expected based on other research. Also, by only reporting on 12 month data there is no 
indication about the duration of improvement or remission of prediabetes or T2DM 
following LSG. While the results of this analysis are promising, the small sample size 
limits the ability to make any definitive statements on the effectiveness of LSG on the 
improvement or remission of T2DM. While extensive literature exists on this topic there 
is limited evidence available on predictors of remission; a larger sample may enable the 
identification of factors that predict improvement or remission of prediabetes or T2DM 
following LSG. Any definitive conclusions about the effects of LSG on the long-term 
improvement and remission of prediabetes and T2DM must be deferred until the 
completion of the larger study. 
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It should be noted that while the sample size of this study may seem quite small 
compared to those of the meta-analyses discussed in Chapter 2, examination of the 
individual studies reveals that the sample size is quite reasonable. For example, the meta-
analysis by Wang et al. (2013) has a combined number of 1004 patients in 11 studies; but 
the individual studies have sample sizes ranging from 20 to 210 with five studies 
reporting on less than 40 patients each. Furthermore, the meta-analysis by Li et al. (2013) 
combines 5 studies for a total sample size of 396 patients; however, with the exception of 
1 large study with a sample size of 238 patients, the remaining studies had sample sizes 
ranging from 15 to 60 patients. Thus, the small sample size of the current study appears to 
be not so small after all, and the larger study will eventually follow more patients than 
some of the individual studies included in the aforementioned meta-analyses. 
6.2 Clinical Implications and Knowledge Translation 
 
 The clinical implications for the larger study will be used to inform health care 
professionals on the benefits of bariatric surgery as a metabolic surgery if patients achieve 
improvement or remission of diabetes for a prolonged period of time. It can also inform 
physicians as well as people with T2DM and obesity about another potential treatment 
option for diabetes particularly for individuals that have challenges controlling their 
diabetes with medications or lifestyle interventions. Finally, these results will add to 
current research on LSG from a Canadian health care perspective and could affect the 
triage process for bariatric surgery by identifying which patients may benefit the most 
from surgery and who should be offered surgery first. 
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 This work, as part of the NL BaSco Study, was also a part of the Translational 
Research Program in Bariatric Care (TRPBC), which is a joint initiative of the bariatric 
surgery clinic at Eastern Health and researchers from Memorial University’s Faculty of 
Medicine and School of Pharmacy. This translational research program made it possible 
to interact with the multidisciplinary bariatric surgery clinical team as well as policy 
makers and other researchers involved in bariatric care in NL throughout this study. Study 
findings were disseminated to the TRBC team via formal presentations at quarterly 
meetings. An active knowledge translation program resulted in changes to data collection 
for the clinical and research team via discussions with the primary investigators and the 
research nurse. While performing an extensive literature review it became evident that the 
duration of diabetes could be an important factor in predicting the likelihood of patients 
experiencing remission of T2DM following bariatric surgery. This data was not being 
collected initially but is now integrated with the standardized abstraction form.  
The results of this study have been presented both locally and nationally. Locally, 
research findings were disseminated through presentations to the TRPBC team, Clinical 
Epidemiology Seminar Series, the CIHR Research Planning Meeting for the NL BaSco 
Study, surgery grand rounds at the Health Sciences Centre in Eastern Health, and the 
Women In Science & Engineering Speaker Series. Study findings were disseminated 
nationally at the Canadian Society for Epidemiology and Biostatistics Student Conference 
2013 in St. John’s, NL, the Canadian Obesity Network’s 8th Obesity Boot Camp 2013 in 
Kananaskis, Alberta, the Canadian Obesity Network’s 3rd Canadian Obesity Summit in 
Vancouver, British Columbia, and the Canadian Obesity Student Meeting 2014 in 
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Waterloo, Ontario. Finally, a manuscript will be prepared for publication and will be 
submitted to the Canadian Journal of Diabetes for peer review in the fall of 2014. 
6.3 Future Research 
 
 Future research on the effect of bariatric surgery on prediabetes and T2DM will be 
increasingly important and relevant as the prevalence of obesity and diabetes continues to 
rise. Agreeing on standard definitions for improvement and remission of prediabetes and 
T2DM will be essential for future research. Without a standard definition, it is hard to 
compare study results and to truly understand the effect of bariatric surgery on 
prediabetes and T2DM. It is also important to study the effects of bariatric surgery not 
only on T2DM but also on prediabetes. If it is indeed found that patients with prediabetes 
are able to achieve normal glycemic measures following bariatric surgery, the incidence 
of T2DM could decrease and triage for bariatric surgery patients may also change. 
However, before research in this area can affect health care practices and LSG can be 
recommended as a treatment for T2DM there is a need for more long-term studies on 
LSG from a Canadian health care perspective to evaluate the duration of improvement or 
remission experienced by patients following surgery and explore potential pre-operative 
predictive factors for remission. 
6.4 Conclusions 
 
 Patients living with obesity and either prediabetes or T2DM who seek bariatric 
surgery as a means of losing weight may experience improvements in glycemic control, 
reductions in antidiabetic medications, or remission of prediabetes or T2DM within the 
first 12 months post-surgery. Patients may also experience improvements in blood 
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pressure, and levels of serum triglycerides and HDL. While the results from this study 
show positive outcomes for patients living with prediabetes or T2DM almost immediately 
after surgery, more research with larger sample sizes is needed to determine the long-term 
implications of bariatric surgery on diabetes complications, diabetes prevalence, 
mortality, etc. before bariatric surgery can be considered as a treatment for prediabetes or 
T2DM.  
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